Disease Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

ID DOID:60081
Name triple-receptor negative breast cancer
Definition A breast cancer that is characterized by the absence of estrogen, progresterone and Her2 receptors.
Source DiseaseOntology.org
Alt Ids
Path disease disease of cellular proliferation cancer organ system cancer thoracic cancer breast cancer triple-receptor negative breast cancer

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile Therapy Indication/Tumor Type Response Type Profile Response Detail
PTEN loss AZD8186 triple-receptor negative breast cancer predicted - sensitive detail...
PTEN loss AZD6482 + Talazoparib triple-receptor negative breast cancer sensitive detail...
PTEN loss AZD6482 + Niraparib triple-receptor negative breast cancer sensitive detail...
PTEN loss AZD6482 + Olaparib triple-receptor negative breast cancer sensitive detail...
PTEN loss AZD6482 + Rucaparib triple-receptor negative breast cancer sensitive detail...
PTEN loss AZD6482 + Veliparib triple-receptor negative breast cancer sensitive detail...
PIK3CA mutant Palbociclib + Pictilisib triple-receptor negative breast cancer sensitive detail...
PIK3CA wild-type Palbociclib + Pictilisib triple-receptor negative breast cancer no benefit detail...
PTEN loss RB1 loss Palbociclib + Pictilisib triple-receptor negative breast cancer no benefit detail...
PTEN loss RB1 loss Pictilisib triple-receptor negative breast cancer resistant detail...
PTEN loss RB1 loss Palbociclib triple-receptor negative breast cancer resistant detail...
JAK2 over exp NVP-BSK805 + Paclitaxel triple-receptor negative breast cancer sensitive detail...
JAK2 amp NVP-BSK805 + Paclitaxel triple-receptor negative breast cancer sensitive detail...
JAK2 amp NVP-BSK805 triple-receptor negative breast cancer sensitive detail...
TP53 R280K YW3-56 triple-receptor negative breast cancer sensitive detail...
PIK3CA mutant Pictilisib triple-receptor negative breast cancer sensitive detail...
PIK3CA amp Linsitinib + Pictilisib triple-receptor negative breast cancer sensitive detail...
PIK3CA amp NVP-AEW541 + Pictilisib triple-receptor negative breast cancer sensitive detail...
TP53 mutant Carboplatin + Nutlin-3a triple-receptor negative breast cancer predicted - sensitive detail...
PIK3CA H1047R PTEN loss ABT-737 + Dactolisib triple-receptor negative breast cancer predicted - sensitive detail...
PIK3CA H1047R PTEN loss ABT-737 + Sapanisertib triple-receptor negative breast cancer predicted - sensitive detail...
PTEN loss M2698 triple-receptor negative breast cancer sensitive detail...
PTEN A72fs DHM25 triple-receptor negative breast cancer sensitive detail...
PTEN V275* DHM25 triple-receptor negative breast cancer sensitive detail...
PIK3CA act mut Bevacizumab + Doxorubicin + Everolimus triple-receptor negative breast cancer predicted - sensitive detail...
PIK3CA act mut Bevacizumab + Doxorubicin + Temsirolimus triple-receptor negative breast cancer predicted - sensitive detail...
TP53 mutant Doxorubicin + Seliciclib triple-receptor negative breast cancer predicted - sensitive detail...
TP53 mutant GDC-0425 + Gemcitabine triple-receptor negative breast cancer predicted - sensitive detail...
PTEN dec exp Ipatasertib + Paclitaxel triple-receptor negative breast cancer predicted - sensitive detail...
MDM2 amp Pembrolizumab triple-receptor negative breast cancer no benefit detail...
STK11 F354L Everolimus + Exemestane triple-receptor negative breast cancer predicted - sensitive detail...
CD274 positive Atezolizumab + Nab-paclitaxel triple-receptor negative breast cancer sensitive detail...
PTEN inact mut Capivasertib + Paclitaxel triple-receptor negative breast cancer predicted - sensitive detail...
PTEN dec exp Docetaxel + Ipatasertib triple-receptor negative breast cancer sensitive detail...
PTEN dec exp Ipatasertib triple-receptor negative breast cancer sensitive detail...
PIK3CA act mut Capivasertib + Paclitaxel triple-receptor negative breast cancer predicted - sensitive detail...
PTEN loss Capivasertib + Paclitaxel triple-receptor negative breast cancer predicted - sensitive detail...
CD274 positive Pembrolizumab triple-receptor negative breast cancer sensitive detail...
CD274 positive Nab-paclitaxel + Pembrolizumab triple-receptor negative breast cancer sensitive detail...
CD274 positive Paclitaxel + Pembrolizumab triple-receptor negative breast cancer sensitive detail...
CD274 positive Carboplatin + Gemcitabine + Pembrolizumab triple-receptor negative breast cancer sensitive detail...
PIK3CA act mut Ipatasertib + Paclitaxel triple-receptor negative breast cancer no benefit detail...
PTEN inact mut Ipatasertib + Paclitaxel triple-receptor negative breast cancer no benefit detail...
CD274 positive Eribulin + Pembrolizumab triple-receptor negative breast cancer predicted - sensitive detail...
MDM2 C464A YF438 triple-receptor negative breast cancer no benefit detail...
MDM2 positive YF438 triple-receptor negative breast cancer sensitive detail...
MDM2 positive Doxorubicin + YF438 triple-receptor negative breast cancer sensitive detail...
FGFR2 positive Alofanib triple-receptor negative breast cancer sensitive detail...
CDK12 S1236fs Olaparib triple-receptor negative breast cancer predicted - sensitive detail...
BRAF V600E Nab-paclitaxel + Vemurafenib triple-receptor negative breast cancer predicted - sensitive detail...
FGFR1 amp Lucitanib triple-receptor negative breast cancer predicted - sensitive detail...
FGFR1 amp Rogaratinib triple-receptor negative breast cancer no benefit detail...
FGFR2 amp Futibatinib triple-receptor negative breast cancer predicted - sensitive detail...
FGFR2 amp 3D185 triple-receptor negative breast cancer sensitive detail...
PTEN dec exp Alpelisib + Everolimus triple-receptor negative breast cancer predicted - sensitive detail...
PIK3CA amp PTEN H123P Alpelisib + Everolimus triple-receptor negative breast cancer predicted - sensitive detail...
PIK3CA amp PTEN H123P Afatinib + Alpelisib triple-receptor negative breast cancer predicted - sensitive detail...
MDM2 pos TP53 R280K YX-02-030 triple-receptor negative breast cancer sensitive detail...
MDM2 pos TP53 R248Q YX-02-030 triple-receptor negative breast cancer sensitive detail...
MDM2 pos TP53 R175H YX-02-030 triple-receptor negative breast cancer sensitive detail...
MDM2 pos TP53 wild-type YX-02-030 triple-receptor negative breast cancer sensitive detail...
MDM2 pos TP53 G266E YX-02-030 triple-receptor negative breast cancer sensitive detail...
MDM2 pos TP53 R248Q TP53 R267L TP53 R273H YX-02-030 triple-receptor negative breast cancer sensitive detail...
MDM2 pos TP53 D281Y YX-02-030 triple-receptor negative breast cancer sensitive detail...
MDM2 pos TP53 del YX-02-030 triple-receptor negative breast cancer sensitive detail...
FGFR2 Y375C FGFR2 amp Futibatinib triple-receptor negative breast cancer sensitive detail...
FGFR2 Y375C FGFR2 amp Pemigatinib triple-receptor negative breast cancer sensitive detail...
BRAF G464V SIJ777 triple-receptor negative breast cancer sensitive detail...
ATM loss Ceralasertib + Olaparib triple-receptor negative breast cancer predicted - sensitive detail...
CD274 positive Nab-paclitaxel + Toripalimab-tpzi triple-receptor negative breast cancer predicted - sensitive detail...
BRAF V600E Vemurafenib triple-receptor negative breast cancer predicted - sensitive detail...
BRAF V600E Dabrafenib triple-receptor negative breast cancer sensitive detail...
BRAF V600E Trametinib triple-receptor negative breast cancer sensitive detail...
BRAF V600E Binimetinib triple-receptor negative breast cancer sensitive detail...
Clinical Trial Phase Therapies Title Recruitment Status Covered Countries Other Countries
NCT00576654 Phase I Irinotecan Veliparib Veliparib and Irinotecan Hydrochloride in Treating Patients With Cancer That Is Metastatic or Cannot Be Removed by Surgery Active, not recruiting USA 0
NCT00740805 Phase I Aldoxorubicin + Cyclophosphamide + Veliparib Veliparib, Cyclophosphamide, and Doxorubicin Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors or Non-Hodgkin Lymphoma Active, not recruiting USA 0
NCT01116648 Phase Ib/II Olaparib Cediranib + Olaparib Cediranib Maleate and Olaparib in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Peritoneal Cancer or Recurrent Triple-Negative Breast Cancer Active, not recruiting USA 0
NCT01351103 Phase I LGK974 LGK974 + Spartalizumab A Study of LGK974 in Patients With Malignancies Dependent on Wnt Ligands Active, not recruiting USA | ITA | FRA | ESP | DEU | CAN 1
NCT01391143 Phase I MGA271 Safety Study of MGA271 in Refractory Cancer Completed USA 0
NCT01562873 Phase II Ruxolitinib Ruxolitinib in Patients With Breast Cancer Terminated USA 0
NCT01587703 Phase I Molibresib A Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of GSK525762 in Subjects With NUT Midline Carcinoma (NMC) and Other Cancers Completed USA | GBR | FRA | ESP | AUS 2
NCT01623349 Phase I Alpelisib + Olaparib Buparlisib + Olaparib Phase I Study of the Oral PI3kinase Inhibitor BKM120 or BYL719 and the Oral PARP Inhibitor Olaparib in Patients With Recurrent Triple Negative Breast Cancer or High Grade Serous Ovarian Cancer Completed USA 0
NCT01639248 Phase II ENMD-2076 Phase 2 Study - Aurora + Angiogenic Kinase Inhibitor ENMD-2076 in Previously Treated Locally Advanced + Metastatic TNBC Completed USA 1
NCT01653470 Phase I Carboplatin Fluorouracil + Irinotecan + Leucovorin BMS-906024 Paclitaxel Study to Evaluate Safety & Tolerability of BMS-906024 in Combination With Chemotherapy & to Define DLTs & MTD of BMS-906024 in Combination With One of the Following Chemotherapy Regimens; Weekly Paclitaxel, 5FU+Irinotecan or Carboplatin+Paclitaxel in Subjects With Advanced / Metastatic Solid Tumors Completed USA | CAN | BEL 0
NCT01695005 Phase I LY3039478 A Study of LY3039478 in Participants With Advanced Cancer Completed USA | GBR | FRA | ESP | DEU 1
NCT01884285 Phase I AZD8186 Abiraterone + AZD8186 AZD8186 + Vistusertib AZD8186 First Time In Patient Ascending Dose Study Completed USA | GBR | ESP | CAN 0
NCT01920061 Phase I Dacomitinib + Gedatolisib Cisplatin + Gedatolisib Docetaxel + Gedatolisib A Study Of PF-05212384 In Combination With Other Anti-Tumor Agents and in Combination With Cisplatin in Patients With Triple Negative Breast Cancer in an Expansion Arm (TNBC) Completed USA | ITA | GBR | ESP | CAN 0
NCT01928394 Phase Ib/II Ipilimumab + Nivolumab Cobimetinib + Ipilimumab + Nivolumab Nivolumab A Study of Nivolumab by Itself or Nivolumab Combined With Ipilimumab in Patients With Advanced or Metastatic Solid Tumors Active, not recruiting USA | ITA | GBR | ESP | DEU | CAN 2
NCT01931163 Phase II Everolimus NECTAR Everolimus Plus Cisplatin in Triple (-) Breast Cancer Completed USA 0
NCT01938638 Phase I BAY1143572 Open Label Phase I Dose Escalation Study With BAY1143572 in Patients With Advanced Cancer Completed USA 3
NCT01969643 Phase I Ladiratuzumab vedotin Ladiratuzumab vedotin + Trastuzumab A Safety Study of SGN-LIV1A in Breast Cancer Patients Completed USA 0
NCT01982448 Phase II Paclitaxel Cisplatin Cisplatin vs Paclitaxel for Triple Negative Breast Cancer Completed USA 0
NCT01990209 Phase II Orteronel Orteronel as Monotherapy in Patients With Metastatic Breast Cancer (MBC) That Expresses the Androgen Receptor (AR) Completed USA 0
NCT01997333 Phase II Glembatumumab vedotin Capecitabine Study of Glembatumumab Vedotin (CDX-011) in Patients With Metastatic, gpNMB Over-Expressing, Triple Negative Breast Cancer Completed USA | ITA | GBR | FRA | ESP | DEU | CAN | BEL | AUS 0
NCT01999738 Phase I EC1456 Folic Acid-Tubulysin Conjugate EC1456 In Patients With Advanced Solid Tumors Completed USA 0
NCT02000882 Phase II Buparlisib + Capecitabine Capecitabine + BKM120 TNBC BC Brain Met Completed USA 0
NCT02003092 Phase I RX-5902 RX-5902 Treatment of Subjects With Solid Tumors Terminated USA 0
NCT02014337 Phase I Eribulin + Mifepristone Mifepristone and Eribulin in Patients With Metastatic Triple Negative Breast Cancer or Other Specified Solid Tumors Completed USA 0
NCT02032823 Phase III Olaparib Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer (OlympiA) Active, not recruiting USA | ITA | GBR | FRA | ESP | DEU | CAN | BEL | AUT | AUS 14
NCT02071862 Phase I Everolimus + Telaglenastat Erlotinib + Telaglenastat Docetaxel + Telaglenastat Telaglenastat Paclitaxel + Telaglenastat Cabozantinib + Telaglenastat Study of the Glutaminase Inhibitor CB-839 in Solid Tumors Completed USA 0
NCT02078752 Phase I PF-06647263 A Study Of PF-06647263 In Patients With Advanced Solid Tumors Terminated USA 0
NCT02101385 Phase II Randomized Controlled Trial of Genomically Directed Therapy in Patients With Triple Negative Breast Cancer Completed USA 0
NCT02120469 Phase I Eribulin + Everolimus Eribulin Mesylate and Everolimus in Treating Patients With Triple-Negative Metastatic Breast Cancer Completed USA 0
NCT02138812 Phase I BAY1161909 + Paclitaxel Phase I Dose Escalation of Oral BAY1161909 in Combination With Intravenous Paclitaxel Terminated USA 0
NCT02157792 Phase I Berzosertib + Irinotecan Berzosertib + Cisplatin + Gemcitabine Berzosertib + Cisplatin + Etoposide Berzosertib + Cisplatin Berzosertib + Carboplatin + Cisplatin Berzosertib + Gemcitabine M6620 First in Human Study Completed USA | GBR 0
NCT02158507 Phase I Lapatinib + Veliparib Pilot Study of Veliparib (ABT-888) and Lapatinib (Tykerb) in Patients With Metastatic, Triple Negative Breast Cancer Active, not recruiting USA 0
NCT02162719 Phase II Ipatasertib + Paclitaxel Paclitaxel A Study of Ipatasertib (GDC-0068) in Combination With Paclitaxel as Front-line Treatment for Patients With Metastatic Triple-Negative Breast Cancer Completed USA | ITA | FRA | ESP | BEL 3
NCT02178722 Phase Ib/II Epacadostat + Pembrolizumab Study to Explore the Safety, Tolerability and Efficacy of MK-3475 in Combination With INCB024360 in Participants With Selected Cancers Completed USA 0
NCT02187991 Phase II Paclitaxel Alisertib + Paclitaxel Study to Compare Alisertib With Paclitaxel vs. Paclitaxel Alone in Metastatic or Locally Recurrent Breast Cancer Active, not recruiting USA 0
NCT02203513 Phase II Prexasertib A Phase II Single Arm Pilot Study of the Chk1/2 Inhibitor (LY2606368) in BRCA1/2 Mutation Associated Breast or Ovarian Cancer, Triple Negative Breast Cancer, High Grade Serous Ovarian Cancer, and Metastatic Castrate-Resistant Prostate Cancer Terminated USA 0
NCT02208375 Phase Ib/II Capivasertib + Olaparib Olaparib + Vistusertib mTORC1/2 Inhibitor AZD2014 or the Oral AKT Inhibitor AZD5363 for Recurrent Endometrial and Ovarian Active, not recruiting USA 0
NCT02222922 Phase I Avelumab + Cofetuzumab pelidotin Fluconazole Cofetuzumab pelidotin A Study Of PF-06647020 For Adult Patients With Advanced Solid Tumors Completed USA | ESP 0
NCT02264678 Phase Ib/II Ceralasertib Carboplatin + Ceralasertib Ceralasertib + Durvalumab Ceralasertib + Olaparib Ascending Doses of Ceralasertib in Combination With Chemotherapy and/or Novel Anti Cancer Agents Recruiting USA | GBR | FRA | ESP | CAN | BEL | AUS 2
NCT02276443 Phase 0 Molecular Testing and Imaging in Improving Response in Patients With Stage I-III Triple-Negative Breast Cancer Receiving Chemotherapy MDACC Breast Moonshot Initiative Recruiting USA 0
NCT02281409 Phase Ib/II Mogamulizumab Safety, Tolerability, and Immunoregulatory Activity of Mogamulizumab (KW-0761) in Subjects With Advanced and/or Metastatic Solid Tumors Completed USA 0
NCT02299635 Phase II Nirogacestat A Study Evaluating PF-03084014 In Patients With Advanced Breast Cancer With Or Without Notch Alterations Terminated USA | ITA | GBR | ESP 2
NCT02307240 Phase I CUDC-907 Open Label, Multi-center Study to Assess the Safety, Tolerability and Pharmacokinetics of CUDC-907 in Subjects With Advanced/Relapsed Solid Tumors Completed USA 0
NCT02322814 Phase II Cobimetinib + Paclitaxel Paclitaxel Atezolizumab + Cobimetinib + Paclitaxel Atezolizumab + Cobimetinib + Nab-paclitaxel A Study of Cobimetinib Plus Paclitaxel, Cobimetinib Plus Atezolizumab Plus Paclitaxel, or Cobimetinib Plus Atezolizumab Plus Nab-Paclitaxel as Initial Treatment for Participants With Triple-Negative Breast Cancer That Has Spread Terminated USA | ITA | GBR | FRA | ESP | BEL | AUS 6
NCT02358200 Phase I Carboplatin + Paclitaxel + Talazoparib Study of BMN-673 With Carboplatin and Paclitaxel in Patients With Advanced BRCA-mutated Solid Tumor or Triple Negative Metastatic Breast Cancer Terminated USA 0
NCT02365662 Phase I ABBV-221 A Study Evaluating Safety and Pharmacokinetics of ABBV-221 in Subjects With Advanced Solid Tumor Types Likely to Exhibit Elevated Levels of Epidermal Growth Factor Receptor Terminated USA | ESP 0
NCT02366949 Phase I BAY1217389 + Paclitaxel Paclitaxel Phase I Study of Oral BAY 1217389 in Combination With Intravenous Paclitaxel Completed USA 1
NCT02368691 Phase II Enobosarm Efficacy and Safety of GTx-024 in Patients With Androgen Receptor-Positive Triple Negative Breast Cancer (AR+ TNBC) Terminated USA 0
NCT02370238 Phase II Reparixin A Double-blind Study of Paclitaxel in Combination With Reparixin or Placebo for Metastatic Triple-Negative Breast Cancer Completed USA | ITA | FRA | ESP | BEL 2
NCT02375958 Phase I PCA062 PCA062 in pCAD-positive Tumors. Completed USA | ITA | FRA | ESP 2
NCT02393794 Phase Ib/II Cisplatin + Nivolumab + Romidepsin Cisplatin + Romidepsin Cisplatin Plus Romidepsin & Nivolumab in Locally Recurrent or Metastatic Triple Negative Breast Cancer (TNBC) Active, not recruiting USA 0
NCT02401347 Phase II Talazoparib Phase II Trial of Talazoparib in BRCA1/2 Wild-type HER2-negative Breast Cancer and Other Solid Tumors Completed USA 0
NCT02411656 Phase II Pembrolizumab Pembrolizumab in Treating Patients With Stage IV Metastatic or Recurrent Inflammatory Breast Cancer or Triple-Negative Breast Cancer Who Have Achieved Clinical Response or Stable Disease to Prior Chemotherapy Active, not recruiting USA 0
NCT02419417 Phase Ib/II BMS986158 Paclitaxel Study of BMS-986158 in Subjects With Select Advanced Solid Tumors Completed USA | FRA | ESP | CAN | AUS 0
NCT02425891 Phase III Atezolizumab + Nab-paclitaxel Nab-paclitaxel A Study of Atezolizumab in Combination With Nab-Paclitaxel Compared With Placebo With Nab-Paclitaxel for Participants With Previously Untreated Metastatic Triple-Negative Breast Cancer (IMpassion130) Completed USA | ITA | GBR | FRA | ESP | DEU | CAN | BEL | AUT | AUS 30
NCT02427581 Phase I Poly ICLC Safety and Immunogenicity of a Personalized Synthetic Long Peptide Breast Cancer Vaccine Strategy in Patients With Persistent Triple-Negative Breast Cancer Following Neoadjuvant Chemotherapy Withdrawn 0
NCT02432963 Phase I MVAp53 + Pembrolizumab Vaccine Therapy and Pembrolizumab in Treating Patients With Solid Tumors That Have Failed Prior Therapy Active, not recruiting USA 0
NCT02435680 Phase II MCS110 Carboplatin + Gemcitabine Efficacy Study of MCS110 Given With Carboplatin and Gemcitabine in Advanced Triple Negative Breast Cancer (TNBC) Completed USA | ITA | FRA | ESP | DEU | BEL | AUT | AUS 4
NCT02447003 Phase II Pembrolizumab Study of Pembrolizumab (MK-3475) Monotherapy for Metastatic Triple-Negative Breast Cancer (MK-3475-086/KEYNOTE-086) Completed 0
NCT02452424 Phase Ib/II Pembrolizumab + Pexidartinib A Combination Clinical Study of PLX3397 and Pembrolizumab To Treat Advanced Melanoma and Other Solid Tumors Terminated USA 0
NCT02456857 Phase II Bevacizumab Everolimus Pegylated liposomal doxorubicin Liposomal Doxorubicin, Bevacizumab, and Everolimus in Patients With Locally Advanced TNBC With Tumors Predicted Insensitive to Standard Chemotherapy; A Moonshot Initiative Completed USA 0
NCT02457910 Phase Ib/II Enzalutamide Enzalutamide + Taselisib Taselisib and Enzalutamide in Treating Patients With Androgen Receptor Positive Triple-Negative Metastatic Breast Cancer Terminated USA 0
NCT02471846 Phase I Navoximod Atezolizumab A Study of GDC-0919 and MPDL3280A Combination Treatment in Participants With Locally Advanced or Metastatic Solid Tumors Completed USA | FRA | ESP 1
NCT02474173 Phase I Paclitaxel Onalespib Onalespib and Paclitaxel in Treating Patients With Advanced Triple Negative Breast Cancer Terminated USA 0
NCT02489448 Phase Ib/II Durvalumab + Nab-paclitaxel Cyclophosphamide + Doxorubicin Neoadjuvant MEDI4736 Concomitant With Weekly Nab-paclitaxel and Dose-dense AC for Stage I-III Triple Negative Breast Cancer Completed USA 0
NCT02498613 Phase II Cediranib + Olaparib A Phase 2 Study of Cediranib in Combination With Olaparib in Advanced Solid Tumors Active, not recruiting USA | CAN 0
NCT02513472 Phase Ib/II Eribulin + Pembrolizumab Study to Evaluate the Efficacy and Safety of Eribulin Mesylate in Combination With Pembrolizumab in Participants With Metastatic Triple-Negative Breast Cancer (mTNBC) (ENHANCE-1) Completed USA 0
NCT02528357 Phase I GSK3174998 Pembrolizumab GSK3174998 Alone or With Pembrolizumab in Subjects With Advanced Solid Tumors Completed USA | FRA | CAN 1
NCT02530489 Phase II Atezolizumab + Nab-paclitaxel Nab-Paclitaxel and Atezolizumab Before Surgery in Treating Patients With Triple Negative Breast Cancer Active, not recruiting USA 0
NCT02531932 Phase II Carboplatin Everolimus Comparison of Single-Agent Carboplatin vs the Combination of Carboplatin and Everolimus for the Treatment of Advanced Triple-Negative Breast Cancer Active, not recruiting USA 0
NCT02540291 Phase I E7046 Study of E7046 in Subjects With Selected Advanced Malignancies Terminated USA | FRA 0
NCT02543645 Phase Ib/II Atezolizumab + Varlilumab A Study of Varlilumab and Atezolizumab in Patients With Advanced Cancer Terminated USA 0
NCT02554812 Phase Ib/II Avelumab + PF-04518600 Avelumab + PD 0360324 Avelumab + Utomilumab Avelumab + PF-04518600 + Utomilumab A Study Of Avelumab In Combination With Other Cancer Immunotherapies In Advanced Malignancies (JAVELIN Medley) Terminated USA | GBR | FRA | CAN | AUS 3
NCT02555657 Phase III Pembrolizumab Eribulin Gemcitabine Vinorelbine Capecitabine Study of Single Agent Pembrolizumab (MK-3475) Versus Single Agent Chemotherapy for Metastatic Triple Negative Breast Cancer (MK-3475-119/KEYNOTE-119) Completed 0
NCT02559492 Phase I Epacadostat + Itacitinib Itacitinib + Parsaclisib INCB039110 Combined With INCB024360 and/or INCB039110 Combined With INCB050465 in Advanced Solid Tumors Terminated USA 0
NCT02574455 Phase III Sacituzumab govitecan-hziy Capecitabine + Eribulin + Gemcitabine + Vinorelbine ASCENT-Study of Sacituzumab Govitecan in Refractory/Relapsed Triple-Negative Breast Cancer (ASCENT) Completed USA | GBR | FRA | ESP | DEU | CAN | BEL 0
NCT02575781 Phase I SAR428926 A Study of SAR428926 in Patients With Advanced Solid Tumors Completed FRA | ESP 1
NCT02580448 Phase Ib/II Seviteronel A Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of VT-464 in Patients With Advanced Breast Cancer Completed USA 0
NCT02593175 Phase II Carboplatin + Paclitaxel + Panitumumab Women's MoonShot: Neoadjuvant Treatment With PaCT for Patients With Locally Advanced TNBC Active, not recruiting USA 0
NCT02624700 Phase II Pemetrexed Disodium + Sorafenib Study of Pemetrexed and Sorafenib for Recurrent or Metastatic Triple Negative Breast Cancer Terminated USA 0
NCT02627430 Phase I Onalespib + Talazoparib Talazoparib and HSP90 Inhibitor AT13387 in Treating Patients With Metastatic Advanced Solid Tumor or Recurrent Ovarian, Fallopian Tube, Primary Peritoneal, or Triple Negative Breast Cancer Withdrawn 0
NCT02628535 Phase I Obrindatamab Safety Study of MGD009 in B7-H3-expressing Tumors Terminated USA | CAN | AUS 0
NCT02630368 Phase Ib/II Avelumab + Cyclophosphamide + JX-594 Cyclophosphamide + JX-594 Cyclophosphamide A Study of Metronomic CP and JX-594 in Patients With Advanced Breast Cancer and Advanced Soft-tissue Sarcoma (METROmaJX) (METROmaJX) Recruiting FRA 0
NCT02632448 Phase Ib/II Gemcitabine + LY2880070 LY2880070 A Study of LY2880070 in Participants With Advanced or Metastatic Cancer Recruiting USA | CAN 2
NCT02637375 Phase I Cyclophosphamide + Doxorubicin + Paclitaxel Ganetespib A Pilot Preoperative Trial of Ganetespib With Paclitaxel for Triple-Negative Breast Cancer Withdrawn 0
NCT02644369 Phase II Pembrolizumab Study of the Effects of Pembrolizumab in Patients With Advanced Solid Tumors (INSPIRE) Active, not recruiting CAN 0
NCT02646748 Phase I Itacitinib + Pembrolizumab Parsaclisib + Pembrolizumab Pembrolizumab Combined With Itacitinib (INCB039110) and/or Pembrolizumab Combined With INCB050465 in Advanced Solid Tumors Completed USA 0
NCT02648477 Phase II Letrozole + Pembrolizumab Exemestane + Pembrolizumab Anastrozole + Pembrolizumab Doxorubicin + Pembrolizumab Pembrolizumab and Doxorubicin Hydrochloride or Anti-Estrogen Therapy in Treating Patients With Triple-Negative or Hormone Receptor-Positive Metastatic Breast Cancer Active, not recruiting USA 0
NCT02657889 Phase Ib/II Niraparib + Pembrolizumab Niraparib in Combination With Pembrolizumab in Patients With Triple-negative Breast Cancer or Ovarian Cancer (TOPACIO) Completed USA 0
NCT02658214 Phase I Cisplatin + Durvalumab + Fluorouracil + Tremelimumab Durvalumab + Gemcitabine + Nab-paclitaxel + Tremelimumab Durvalumab + Fluorouracil + Leucovorin + Oxaliplatin + Tremelimumab Carboplatin + Durvalumab + Nab-paclitaxel + Tremelimumab Carboplatin + Durvalumab + Etoposide + Tremelimumab Carboplatin + Durvalumab + Paclitaxel + Tremelimumab Carboplatin + Durvalumab + Gemcitabine + Tremelimumab Durvalumab and Tremelimumab in Combination With First-Line Chemotherapy in Advanced Solid Tumors Completed 2
NCT02660034 Phase I Pamiparib + Tislelizumab The Safety, Pharmacokinetics and Antitumor Activity of BGB-A317 in Combination With BGB-290 in Participants With Advanced Solid Tumors Completed USA | GBR | FRA | ESP | AUS 1
NCT02672475 Phase I Galunisertib + Paclitaxel Galunisertib and Paclitaxel in Treating Patients With Metastatic Androgen Receptor Negative (AR-) Triple Negative Breast Cancer Completed USA 0
NCT02676986 Phase II Enzalutamide + Exemestane Exemestane Enzalutamide Short-term Preoperative Treatment With Enzalutamide, Alone or in Combination With Exemestane in Primary Breast Cancer (ARB) Unknown status USA | GBR | ESP | DEU 1
NCT02689427 Phase II Enzalutamide + Paclitaxel Enzalutamide and Paclitaxel Before Surgery in Treating Patients With Stage I-III Androgen Receptor-Positive Triple-Negative Breast Cancer Completed USA 0
NCT02698176 Phase I Birabresib A Dose Exploration Study With MK-8628 in Participants With Selected Advanced Solid Tumors (MK-8628-006) Terminated 0
NCT02706392 Phase I Cyclophosphamide + Fludarabine + ROR1 CAR-T cells Genetically Modified T-Cell Therapy in Treating Patients With Advanced ROR1+ Malignancies Terminated USA 0
NCT02708680 Phase Ib/II Atezolizumab Atezolizumab + Entinostat Randomized Phase 2 Study of Atezolizumab and Entinostat in Patients With aTN Breast Cancer With Phase 1b Lead In Completed USA 1
NCT02719691 Phase I Alisertib + Sapanisertib Phase I Study of MLN0128 and MLN8237 in Patients With Advanced Solid Tumors and Metastatic Triple-negative Breast Cancer Completed USA 0
NCT02720185 Phase II Dasatinib Window of Opportunity Trial of Dasatinib in Operable Triple Negative Breast Cancers With nEGFR Terminated USA 0
NCT02730130 Phase II Pembrolizumab Study to Assess the Efficacy of Pembrolizumab Plus Radiotherapy in Metastatic Triple Negative Breast Cancer Patients Completed USA 0
NCT02734290 Phase Ib/II Capecitabine + Pembrolizumab Paclitaxel + Pembrolizumab Standard of Care Chemotherapy Plus Pembrolizumab for Breast Cancer Active, not recruiting USA 0
NCT02750358 Phase II Enzalutamide Feasibility Study of Adjuvant Enzalutamide for the Treatment of Early Stage AR (+) Triple Negative Breast Cancer Active, not recruiting USA 0
NCT02752685 Phase II Nab-paclitaxel + Pembrolizumab Phase II Study of Pembrolizumab and Nab-paclitaxel in HER-2 Negative Metastatic Breast Cancer Active, not recruiting USA 0
NCT02755272 Phase II Pembrolizumab Carboplatin + Gemcitabine A Study of Pembrolizumab With Carboplatin and Gemcitabine in Patients With Metastatic Triple Negative Breast Cancer Active, not recruiting USA 0
NCT02760797 Phase I Emactuzumab + Selicrelumab A Study of Emactuzumab and RO7009789 Administered in Combination in Participants With Advanced Solid Tumors Completed USA | FRA | BEL 0
NCT02761694 Phase I ARQ 751 + Paclitaxel ARQ 751 ARQ 751 + Fulvestrant ARQ 751 as a Single Agent or in Combination With Other Anti-Cancer Agents, in Solid Tumors With PIK3CA / AKT / PTEN Mutations Terminated USA 0
NCT02762981 Phase Ib/II Nab-paclitaxel + Relacorilant Study to Evaluate CORT125134 in Combination With Nab-paclitaxel in Patients With Solid Tumors Completed USA 0
NCT02768701 Phase II Cyclophosphamide + Pembrolizumab Study Of Single-dose Cyclophosphamide +Pembrolizumab In Patients With Metastatic Triple Negative Breast Cancer Completed USA 0
NCT02783300 Phase I GSK3326595 Dose Escalation Study of GSK3326595 in Participants With Solid Tumors and Non-Hodgkin's Lymphoma (NHL) Completed USA | FRA | CAN 1
NCT02784795 Phase I Cisplatin + Gemcitabine + LY3039478 Carboplatin + Gemcitabine + LY3039478 LY3023414 + LY3039478 Abemaciclib + LY3039478 LY3039478 + Taladegib LY3039478 LY3023414 A Study of LY3039478 in Participants With Advanced or Metastatic Solid Tumors Completed USA | FRA | ESP 1
NCT02788981 Phase II Mifepristone + Nab-paclitaxel Nab-paclitaxel Abraxane With or Without Mifepristone for Advanced, Glucocorticoid Receptor-Positive, Triple-Negative Breast Cancer Active, not recruiting USA 0
NCT02807844 Phase Ib/II MCS110 + Spartalizumab Phase Ib/II Study of MCS110 in Combination With PDR001 in Patients With Advanced Malignancies Completed USA | ITA | FRA | ESP | DEU | BEL 5
NCT02819518 Phase III Paclitaxel Pembrolizumab Nab-paclitaxel Carboplatin + Gemcitabine Study of Pembrolizumab (MK-3475) Plus Chemotherapy vs. Placebo Plus Chemotherapy for Previously Untreated Locally Recurrent Inoperable or Metastatic Triple Negative Breast Cancer (MK-3475-355/KEYNOTE-355) Completed 0
NCT02824042 Phase I Anetumab ravtansine + Itraconazole Anetumab ravtansine Thorough ECG (Electrocardiogram) and Drug Interaction Study With Anetumab Ravtansine and Itraconazole Completed USA | FRA | ESP | BEL | AUS 1
NCT02826434 Phase I Durvalumab + Poly ICLC + PVX-410 Adjuvant PVX-410 Vaccine and Durvalumab in Stage II/III Triple Negative Breast Cancer Active, not recruiting USA 0
NCT02829723 Phase Ib/II BLZ945 BLZ945 + Spartalizumab Phase I/II Study of BLZ945 Single Agent or BLZ945 in Combination With PDR001 in Advanced Solid Tumors Terminated USA | ITA | ESP 5
NCT02834247 Phase I Mivavotinib + Nivolumab A Study of TAK-659 in Combination With Nivolumab in Participants With Advanced Solid Tumors Terminated USA | ITA | GBR | ESP 0
NCT02834403 Phase Ib/II Pegfilgrastim Docetaxel + L-NMMA L-NMMA Plus Taxane Chemotherapy in Refractory Locally Advanced or Metastatic Triple Negative Breast Cancer Patients Completed USA 0
NCT02876107 Phase II Cyclophosphamide + Doxorubicin Carboplatin + Paclitaxel + Panitumumab Carboplatin + Paclitaxel Carboplatin and Paclitaxel With or Without Panitumumab in Treating Patients With Invasive Triple Negative Breast Cancer Active, not recruiting USA 0
NCT02876302 Phase II Cyclophosphamide + Doxorubicin + Paclitaxel + Ruxolitinib Study Of Ruxolitinib (INCB018424) With Preoperative Chemotherapy For Triple Negative Inflammatory Breast Cancer Active, not recruiting USA 0
NCT02880371 Phase Ib/II ARRY-382 + Pembrolizumab A Study of ARRY-382 in Combination With Pembrolizumab for the Treatment of Patients With Advanced Solid Tumors Terminated USA 0
NCT02883062 Phase II Carboplatin + Paclitaxel Atezolizumab + Carboplatin + Paclitaxel Carboplatin and Paclitaxel With or Without Atezolizumab Before Surgery in Treating Patients With Newly Diagnosed, Stage II-III Triple-Negative Breast Cancer Active, not recruiting USA 0
NCT02890069 Phase I LCL161 + Spartalizumab Everolimus + Spartalizumab Panobinostat + Spartalizumab A Study of PDR001 in Combination With LCL161, Everolimus or Panobinostat Completed USA | GBR | ESP | DEU 3
NCT02898207 Phase I Olaparib + Onalespib Olaparib and Onalespib in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery or Recurrent Ovarian, Fallopian Tube, Primary Peritoneal, or Triple-Negative Breast Cancer Completed USA 0
NCT02900664 Phase I Nazartinib + Spartalizumab CJM112 + Spartalizumab Spartalizumab + Trametinib Canakinumab + Spartalizumab Canakinumab A Study of PDR001 in Combination With CJM112, EGF816, Ilaris (Canakinumab) or Mekinist (Trametinib) Completed USA | ITA | FRA | ESP | CAN | BEL 3
NCT02926690 Phase I OTS167 Safety Study of MELK Inhibitor to Treat Patients With Advanced Breast Cancer and Triple Negative Breast Cancer Recruiting USA 0
NCT02929576 Phase III Paclitaxel Enzalutamide + Paclitaxel Enzalutamide Efficacy and Safety Study of Enzalutamide in Combination With Paclitaxel Chemotherapy or as Monotherapy Versus Placebo With Paclitaxel in Patients With Advanced, Diagnostic-Positive, Triple-Negative Breast Cancer (ENDEAR) Withdrawn USA 0
NCT02936102 Phase I FAZ053 FAZ053 + Spartalizumab A Study of FAZ053 Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies. Active, not recruiting USA | ITA | FRA | ESP | CAN 4
NCT02938442 Phase II Montanide ISA 51 + P10s-PADRE Vaccination of Triple Negative Breast Cancer Patients Completed USA 0
NCT02947165 Phase I NIS793 + Spartalizumab NIS793 Phase I/Ib Study of NIS793 in Combination With PDR001 in Patients With Advanced Malignancies. Completed USA | ITA | DEU | CAN | AUT 4
NCT02950064 Phase I BTP-114 A Study to Determine the Safety of BTP-114 for Treatment in Patients With Advanced Solid Tumors With BRCA Mutations Unknown status USA 0
NCT02952248 Phase I Ezabenlimab A Trial to Find and Investigate a Safe Dose of a New Substance (BI 754091) for Patients With Solid Tumours Completed USA | GBR | CAN 0
NCT02954874 Phase III Pembrolizumab Testing MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer Active, not recruiting USA | CAN 1
NCT02971761 Phase II Enobosarm + Pembrolizumab Pembrolizumab and Enobosarm in Treating Patients With Androgen Receptor Positive Metastatic Triple Negative Breast Cancer Completed USA 0
NCT02977156 Phase I Ipilimumab + JX-594 Immunization Strategy With Intra-tumoral Injections of Pexa-Vec With Ipilimumab in Metastatic / Advanced Solid Tumors. (ISI-JX) Completed FRA 0
NCT02977468 Phase I Pembrolizumab Effects of MK-3475 (Pembrolizumab) on the Breast Tumor Microenvironment in Triple Negative Breast Cancer (Pembro/IORT) Recruiting USA 0
NCT02978716 Phase II Carboplatin + Gemcitabine Carboplatin + Gemcitabine + Trilaciclib Trilaciclib (G1T28), a CDK 4/6 Inhibitor, in Combination With Gemcitabine and Carboplatin in Metastatic Triple Negative Breast Cancer (mTNBC) Terminated USA | BEL 6
NCT02981303 Phase II Pembrolizumab + PGG beta-glucan Study of Imprime PGG and Pembrolizumab in Advanced Melanoma and Triple Negative Breast Cancer Completed USA 0
NCT02984683 Phase II SAR566658 Study Evaluating Efficacy and Safety of SAR566658 Treatment in Patients With CA6 Positive Metastatic Triple Negative Breast Cancer Terminated ITA | ESP | BEL 2
NCT02985658 Phase I Cisplatin Veliparib Vinorelbine Expanded Access With ABT-888 (Veliparib) to Treat Metastatic Breast Cancer No longer available USA 0
NCT02996825 Phase I Gemcitabine + Mirvetuximab Soravtansine Mirvetuximab Soravtansine and Gemcitabine Hydrochloride in Treating Patients With FRalpha-Positive Recurrent Ovarian, Primary Peritoneal, Fallopian Tube, Endometrial, or Triple Negative Breast Cancer Completed USA 0
NCT03004183 Phase II Pembrolizumab AdV-tk + Valacyclovir SBRT and Oncolytic Virus Therapy Before Pembrolizumab for Metastatic TNBC and NSCLC (STOMP) Completed USA 0
NCT03012100 Phase II Cyclophosphamide + Sargramostim Cyclophosphamide + FR alpha peptide vaccine + Sargramostim Multi-epitope Folate Receptor Alpha Peptide Vaccine, GM-CSF, and Cyclophosphamide in Treating Patients With Triple Negative Breast Cancer Active, not recruiting USA 0
NCT03012230 Phase I Pembrolizumab + Ruxolitinib Pembrolizumab and Ruxolitinib Phosphate in Treating Patients With Metastatic Stage IV Triple Negative Breast Cancer Completed USA 0
NCT03012477 Phase II Adavosertib + Cisplatin CISPLATIN + AZD-1775 In Breast Cancer Completed USA 0
NCT03018405 Phase Ib/II NKR-2 cells A Dose Escalation Phase I Study to Assess the Safety and Clinical Activity of Multiple Cancer Indications (THINK) Unknown status USA | BEL 0
NCT03036488 Phase III Cyclophosphamide + Epirubicin Cyclophosphamide + Doxorubicin Pembrolizumab Carboplatin + Paclitaxel Study of Pembrolizumab (MK-3475) Plus Chemotherapy vs Placebo Plus Chemotherapy as Neoadjuvant Therapy and Pembrolizumab vs Placebo as Adjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC) (MK-3475-522/KEYNOTE-522) Active, not recruiting USA | ITA | GBR | FRA | ESP | DEU | CAN | AUS 13
NCT03044730 Phase II Capecitabine + Pembrolizumab Pembrolizumab and Capecitabine in Treating Patients With Locally Advanced or Metastatic Triple Negative or Hormone-Refractory Breast Cancer That Cannot Be Removed by Surgery Unknown status USA 0
NCT03076372 Phase I MM-310 A Study Evaluating MM-310 in Patients With Solid Tumors Unknown status USA 0
NCT03090165 Phase Ib/II Bicalutamide + Ribociclib Ribociclib and Bicalutamide in AR+ TNBC Recruiting USA 0
NCT03095352 Phase II Carboplatin + Pembrolizumab + Trastuzumab Carboplatin Carboplatin + Trastuzumab Carboplatin + Pembrolizumab Pembrolizumab With Carboplatin Compared to Carboplatin Alone in Breast Cancer Patients With Chest Wall Disease Recruiting USA 0
NCT03096054 Phase I LY3143921 A CR-UK Phase I Trial of LY3143921 Active, not recruiting GBR 0
NCT03098550 Phase Ib/II Daratumumab + Nivolumab A Study to Test the Safety and Effectiveness of Nivolumab Combined With Daratumumab in Patients With Advanced Solid Tumors or Tumors That Have Spread Completed USA | ITA | FRA | ESP | DEU | CAN | AUS 2
NCT03102320 Phase I Anetumab ravtansine Anetumab ravtansine + Gemcitabine Anetumab ravtansine + Cisplatin Phase 1b Multi-indication Study of Anetumab Ravtansine in Mesothelin Expressing Advanced Solid Tumors (ARCS-Multi) Completed USA | ITA | GBR | FRA | ESP | CAN | BEL | AUS 4
NCT03106077 Phase II Mirvetuximab Soravtansine Mirvetuximab Soravtansine in Localized Triple-Negative Breast Cancer (TNBC) Completed USA 0
NCT03106415 Phase Ib/II Binimetinib + Pembrolizumab Pembrolizumab and Binimetinib in Treating Patients With Locally Advanced or Metastatic Triple Negative Breast Cancer Completed USA 0
NCT03121352 Phase II Carboplatin + Nab-paclitaxel + Pembrolizumab Carboplatin, Nab-Paclitaxel and Pembrolizumab for Metastatic Triple-Negative Breast Cancer Completed USA 0
NCT03125902 Phase III Paclitaxel Atezolizumab + Paclitaxel A Study of Atezolizumab and Paclitaxel Versus Placebo and Paclitaxel in Participants With Previously Untreated Locally Advanced or Metastatic Triple Negative Breast Cancer (TNBC) (IMpassion131) Completed USA | ITA | GBR | FRA | ESP | DEU | CAN 17
NCT03130439 Phase II Abemaciclib Abemaciclib for Patients With Retinoblastoma-Positive, Triple Negative Metastatic Breast Cancer Terminated USA 0
NCT03150810 Phase Ib/II Pamiparib + Temozolomide Study to Assess Safety, Tolerability and Clinical Activity of BGB-290 in Combination With Temozolomide (TMZ) in Participants With Locally Advanced or Metastatic Solid Tumors Completed USA | GBR | ESP | AUS 0
NCT03167619 Phase II Durvalumab + Olaparib Olaparib Phase II Multicenter Study of Durvalumab and Olaparib in Platinum tReated Advanced Triple Negative Breast Cancer (DORA) (DORA) Completed USA 0
NCT03184558 Phase II Bemcentinib + Pembrolizumab BGB324 in Combination With Pembrolizumab in Patients With TNBC Terminated USA | GBR | ESP 1
NCT03193853 Phase II Cisplatin + Nab-paclitaxel Sapanisertib + Serabelisib TAK-228 and TAK-117 Followed by Cisplatin and Nab Paclitaxel for Metastatic Triple Negative Breast Cancer Completed USA 0
NCT03197935 Phase III Pegfilgrastim Doxorubicin Atezolizumab Filgrastim Nab-paclitaxel Cyclophosphamide A Study to Investigate Atezolizumab and Chemotherapy Compared With Placebo and Chemotherapy in the Neoadjuvant Setting in Participants With Early Stage Triple Negative Breast Cancer (IMpassion031) Completed USA | ITA | GBR | ESP | DEU | CAN | BEL | AUS 5
NCT03199040 Phase I Durvalumab Neoantigen DNA Vaccine Alone vs. Neoantigen DNA Vaccine Plus Durvalumab in Triple Negative Breast Cancer Patients Following Standard of Care Therapy Terminated USA 0
NCT03205761 Phase II Olaparib Analysis of Olaparib Response in Patients With BRCA1 and/or 2 Promoter Methylation Diagnosed of Advanced Breast Cancer (COMETABreast) Completed ESP 0
NCT03206203 Phase II Atezolizumab + Carboplatin Carboplatin Carboplatin With or Without Atezolizumab in Treating Patients With Stage IV Triple Negative Breast Cancer Active, not recruiting USA 0
NCT03207867 Phase II Spartalizumab + Taminadenant A Phase 2 Study of NIR178 in Combination With PDR001 in Patients With Solid Tumors and Non-Hodgkin Lymphoma Terminated USA | ITA | FRA | ESP | DEU | BEL | AUT | AUS 7
NCT03213041 Phase II Carboplatin + Pembrolizumab Pembrolizumab and Carboplatin in Treating Patients With Circulating Tumor Cells Positive Metastatic Breast Cancer Recruiting USA 0
NCT03221400 Phase Ib/II STA-8666 PEN-866 in Patients With Advanced Solid Malignancies Unknown status USA 0
NCT03225547 Phase II Mifepristone + Pembrolizumab Study of Pembrolizumab and Mifepristone in Patients With Advanced HER2-negative Breast Cancer Active, not recruiting USA 0
NCT03243331 Phase I Cofetuzumab pelidotin + Gedatolisib An Initial Safety Study of Gedatolisib Plus PTK7-ADC for Metastatic Triple-negative Breast Cancer Completed USA 0
NCT03256344 Phase I Atezolizumab + Talimogene laherparepvec Study of Talimogene Laherparepvec With Atezolizumab for Triple Negative Breast Cancer and Colorectal Cancer With Liver Metastases Completed USA | ESP | DEU | BEL | AUS 1
NCT03281954 Phase III Atezolizumab Clinical Trial of Neoadjuvant Chemotherapy With Atezolizumab or Placebo in Patients With Triple-Negative Breast Cancer Followed After Surgery by Atezolizumab or Placebo Active, not recruiting USA | CAN 0
NCT03289962 Phase I Autogene cevumeran Atezolizumab + Autogene cevumeran A Study of RO7198457 as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Tumors Active, not recruiting USA | GBR | ESP | DEU | CAN | BEL 2
NCT03292172 Phase I Atezolizumab + TEN-010 A Study to Evaluate the Safety, Pharmacokinetics and Clinical Activity of RO6870810 and Atezolizumab (PD-L1 Antibody) in Participants With Advanced Ovarian Cancer or Triple Negative Breast Cancer Terminated USA | GBR | CAN | AUS 1
NCT03310957 Phase Ib/II Ladiratuzumab vedotin + Pembrolizumab Safety and Efficacy of SGN-LIV1A Plus Pembrolizumab for Patients With Locally-Advanced or Metastatic Triple-Negative Breast Cancer Active, not recruiting USA | ESP | DEU 1
NCT03316586 Phase II Cabozantinib + Nivolumab A Phase II Study of Nivolumab in Combination With Cabozantinib for Metastatic Triple-negative Breast Cancer Completed USA 0
NCT03316794 Phase I SC-005 A Study of SC-005 in Subjects With Triple Negative Breast Cancer (TNBC) Terminated USA 0
NCT03318562 Phase II Tomivosertib A PD Study of Oral eFT508 in Subjects With Advanced TNBC and HCC Terminated USA 0
NCT03330405 Phase II Avelumab + Talazoparib Javelin Parp Medley: Avelumab Plus Talazoparib In Locally Advanced Or Metastatic Solid Tumors Terminated USA | GBR | CAN | BEL | AUS 4
NCT03330847 Phase II Adavosertib + Olaparib Olaparib Ceralasertib + Olaparib To Assess Safety and Efficacy of Agents Targeting DNA Damage Repair With Olaparib Versus Olaparib Monotherapy. Active, not recruiting USA | ITA | GBR | FRA | ESP | DEU | CAN | BEL 7
NCT03337724 Phase II Ipatasertib + Paclitaxel Paclitaxel A Study of Ipatasertib in Combination With Paclitaxel as a Treatment for Participants With PIK3CA/AKT1/PTEN-Altered, Locally Advanced or Metastatic, Triple-Negative Breast Cancer or Hormone Receptor-Positive, HER2-Negative Breast Cancer (IPATunity130) Completed USA | ITA | GBR | FRA | ESP | DEU | CAN | BEL | AUS 21
NCT03356860 Phase Ib/II Cyclophosphamide + Durvalumab + Epirubicin + Paclitaxel Cyclophosphamide + Epirubicin + Paclitaxel Safety and Efficacy of Durvalumab Combined to Neoadjuvant Chemotherapy in Localized Luminal B HER2(-) and Triple Negative Breast Cancer. (B-IMMUNE) Completed BEL 0
NCT03361800 Phase I Entinostat Window of Opportunity Trial of Entinostat in Patients With Newly Diagnosed Stage I-IIIC,TNBC Terminated USA 0
NCT03362060 Phase I Pembrolizumab + PVX-410 PVX-410 Vaccine Plus Pembrolizumab in HLA-A2+ Metastatic Triple Negative Breast Cancer Active, not recruiting USA 0
NCT03363893 Phase Ib/II Samuraciclib Fulvestrant + Samuraciclib Modular Study to Evaluate CT7001 Alone in Cancer Patients With Advanced Malignancies Completed USA | GBR 0
NCT03366844 Phase Ib/II Pembrolizumab Breast Cancer Study of Preoperative Pembrolizumab + Radiation Active, not recruiting USA 0
NCT03371017 Phase III Atezolizumab + Capecitabine + Carboplatin + Gemcitabine Capecitabine + Carboplatin + Gemcitabine A Study of the Efficacy and Safety of Atezolizumab Plus Chemotherapy for Patients With Early Relapsing Recurrent Triple-Negative Breast Cancer (IMpassion132) Active, not recruiting USA | ITA | GBR | FRA | ESP | DEU 22
NCT03383679 Phase II Darolutamide Capecitabine Study on Androgen Receptor and Triple Negative Breast Cancer (START) Completed FRA 0
NCT03387085 Phase Ib/II ETBX-051 Aldoxorubicin ETBX-061 Cisplatin Cyclophosphamide haNK cells GI-4000 Bevacizumab ALT-803 Fluorouracil ETBX-011 Oxaliplatin Capecitabine Leucovorin GI-6301 Nab-paclitaxel Avelumab GI-6207 QUILT-3.067: NANT Triple Negative Breast Cancer (TNBC) Vaccine: Molecularly Informed Integrated Immunotherapy in Subjects With TNBC Who Have Progressed on or After Standard-of-care Therapy. Active, not recruiting USA 0
NCT03414684 Phase II Carboplatin + Nivolumab Carboplatin Carboplatin +/- Nivolumab in Metastatic Triple Negative Breast Cancer Active, not recruiting USA 0
NCT03424005 Phase Ib/II Atezolizumab + Bevacizumab + Selicrelumab Atezolizumab + RO6874281 Atezolizumab + Bevacizumab Atezolizumab + Carboplatin + Gemcitabine Atezolizumab + Eribulin Capecitabine Atezolizumab Atezolizumab + Bevacizumab + Cobimetinib Atezolizumab + Capecitabine Atezolizumab + Ipatasertib Atezolizumab + Ladiratuzumab vedotin A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Metastatic or Inoperable Locally Advanced Triple-Negative Breast Cancer (Morpheus-TNBC) (Morpheus-TNBC) Recruiting USA | GBR | FRA | ESP | DEU | AUS 2
NCT03435640 Phase Ib/II NKTR-214 + NKTR-262 Nivolumab + NKTR-214 + NKTR-262 A Study of NKTR-262 in Combination With NKTR-214 and With NKTR-214 Plus Nivolumab in Patients With Locally Advanced or Metastatic Solid Tumor Malignancies Terminated USA 0
NCT03454451 Phase I CPI-006 CPI-006 + Pembrolizumab CPI-006 + CPI-444 CPI-006 Alone and in Combination With Ciforadenant and With Pembrolizumab for Patients With Advanced Cancers Completed USA | AUS 0
NCT03464942 Phase II Atezolizumab Stereotactic Radiation and Immunotherapy in Patients With Advanced Triple Negative Breast Cancer (AZTEC) Completed AUS 0
NCT03483012 Phase II Atezolizumab Atezolizumab + Stereotactic Radiation in Triple-negative Breast Cancer and Brain Metastasis Active, not recruiting USA 0
NCT03487666 Phase II Capecitabine + Nivolumab Capecitabine Nivolumab OXEL: Immune Checkpoint or Capecitabine or Combination Therapy as Adjuvant Therapy for TNBC With Residual Disease Active, not recruiting USA 0
NCT03498716 Phase III Atezolizumab + Cyclophosphamide + Epirubicin + Paclitaxel Cyclophosphamide + Epirubicin + Paclitaxel Cyclophosphamide + Doxorubicin + Paclitaxel Atezolizumab + Cyclophosphamide + Doxorubicin + Paclitaxel A Study Comparing Atezolizumab (Anti PD-L1 Antibody) In Combination With Adjuvant Anthracycline/Taxane-Based Chemotherapy Versus Chemotherapy Alone In Patients With Operable Triple-Negative Breast Cancer (IMpassion030) Completed USA | ITA | GBR | FRA | ESP | DEU | BEL | AUT | AUS 22
NCT03499899 Phase II Carboplatin + Ieramilimab Carboplatin + Ieramilimab + Spartalizumab Ieramilimab + Spartalizumab A Study of Efficacy and Safety of LAG525 in Combination With Spartalizumab, or With Spartalizumab and Carboplatin, or With Carboplatin, in Patients With Advanced Triple-negative Breast Cancer Completed USA | ITA | FRA | ESP | DEU | CAN | BEL | AUS 9
NCT03504488 Phase Ib/II BA3021 CAB-ROR2-ADC Safety and Efficacy Study in Patients With Solid Tumors Recruiting USA | ITA | ESP | DEU 4
NCT03517488 Phase I XmAb20717 A Study of XmAb20717 in Subjects With Selected Advanced Solid Tumors (DUET-2) Completed USA 0
NCT03519178 Phase II PF-06873600 A Study of PF-06873600 in People With Cancer Active, not recruiting USA | CAN 4
NCT03538028 Phase I INCAGN02385 A Safety and Tolerability Study of INCAGN02385 in Select Advanced Malignancies Completed USA 0
NCT03542175 Phase I Rucaparib A Study of Rucaparib Administered With Radiation in Patients With Triple Negative Breast Cancer With an Incomplete Response Following Chemotherapy Active, not recruiting USA 0
NCT03544125 Phase I Durvalumab + Olaparib Olaparib and Durvalumab in Treating Participants With Metastatic Triple Negative Breast Cancer Completed USA 0
NCT03546686 Phase II Ipilimumab + Nivolumab Peri-Operative Ipilimumab+Nivolumab and Cryoablation in Women With Triple-negative Breast Cancer Recruiting USA 0
NCT03554109 Phase II Aldoxorubicin + ALT-803 + Avelumab + Cyclophosphamide + ETBX-011 + ETBX-051 + ETBX-061 + Fluorouracil + GI-4000 + GI-6207 + GI-6301 + haNK cells + Leucovorin + Nab-paclitaxel Cyclophosphamide + Doxorubicin + Paclitaxel QUILT-3.057: NANT Neoadjuvant Triple- Negative Breast Cancer (TNBC) Vaccine Withdrawn USA 0
NCT03562637 Phase III Adagloxad simolenin + OBI-821 Study of Adagloxad Simolenin (OBI-822)/OBI-821 in the Adjuvant Treatment of Patients With Globo H Positive TNBC Recruiting USA | AUS 11
NCT03564782 Phase I PVSRIPO Examining Bioactivity of PVSRIPO in Invasive Breast Cancer Completed USA 0
NCT03567720 Phase II Pembrolizumab + Tavokinogene telseplasmid Nab-paclitaxel + Pembrolizumab + Tavokinogene telseplasmid Tavo and Pembrolizumab With or Without Chemotherapy in Patients With Inoperable Locally Advanced or Metastatic TNBC Active, not recruiting USA | AUS 0
NCT03579472 Phase I Bintrafusp alfa + Eribulin M7824 and Eribulin Mesylate in Treating Patients With Metastatic Triple Negative Breast Cancer Terminated USA 0
NCT03599453 Phase I Celecoxib + Interferon alpha-2b + Pembrolizumab + Rintatolimod Chemokine Modulation Therapy and Pembrolizumab in Treating Participants With Metastatic Triple-Negative Breast Cancer Completed USA 0
NCT03606967 Phase II Durvalumab + Nab-paclitaxel + Poly ICLC + Tremelimumab + TSMA-based SLP vaccine Nab-paclitaxel Carboplatin + Gemcitabine Durvalumab + Nab-paclitaxel + Tremelimumab Testing the Addition of an Individualized Vaccine to Nab-Paclitaxel, Durvalumab and Tremelimumab and Chemotherapy in Patients With Metastatic Triple Negative Breast Cancer Recruiting USA 0
NCT03616886 Phase Ib/II Carboplatin + Durvalumab + Oleclumab + Paclitaxel Carboplatin + Durvalumab + Paclitaxel Paclitaxel + Carboplatin + Durvalumab With or Without Oleclumab for Previously Untreated Locally Recurrent Inoperable or Metastatic TNBC (SYNERGY) Active, not recruiting FRA | BEL 0
NCT03620643 Phase II Crizotinib Crizotinib + Fulvestrant Crizotinib in Lobular Breast, Diffuse Gastric and Triple Negative Lobular Breast Cancer or CDH1-mutated Solid Tumours (ROLo) Active, not recruiting GBR 0
NCT03621982 Phase I Camidanlumab tesirine Study of ADCT-301 in Patients With Selected Advanced Solid Tumors Terminated USA | GBR | BEL 0
NCT03639948 Phase II Carboplatin + Docetaxel + Pegfilgrastim + Pembrolizumab Neoadjuvant Phase II Study of Pembrolizumab And Carboplatin Plus Docetaxel in Triple Negative Breast Cancer (NeoPACT) Active, not recruiting USA 0
NCT03644589 Phase II Cisplatin + Pembrolizumab Effect of Pembrolizumab and Cisplatin on Metastatic, Locally Recurrent or Inoperable Triple-Negative Breast Cancer Withdrawn USA 0
NCT03654547 Phase I Tinengotinib Safety of TT-00420 Monotherapy in Patients With Advanced Solid Tumors and Triple Negative Breast Cancer Active, not recruiting USA 1
NCT03661632 Phase Ib/II BMS-986310 + Nivolumab An Investigational Immunotherapy Study of BMS-986310 Administered Alone and in Combination With Nivolumab in Patients With Advanced Solid Tumors Completed USA | CAN | BEL 0
NCT03665285 Phase Ib/II NC318 A Safety and Tolerability Study of NC318 in Subjects With Advanced or Metastatic Solid Tumors Completed USA 0
NCT03667716 Phase I COM701 COM701 + Nivolumab COM701 in Subjects With Advanced Solid Tumors Active, not recruiting USA 0
NCT03674242 Phase II Carboplatin + Gemcitabine Carboplatin + Eryaspase + Gemcitabine Study of Eryaspase in Combination With Chemotherapy Versus Chemotherapy Alone as 1st Line Treatment of TNBC (TRYbeCA-2) Terminated ESP | BEL 1
NCT03674567 Phase Ib/II FLX475 + Pembrolizumab FLX475 Dose Escalation and Expansion Study of FLX475 Monotherapy and in Combination With Pembrolizumab Recruiting USA | AUS 4
NCT03674827 Phase I PF-06936308 A Study To Evaluate Escalating Doses of A Vaccine-Based Immunotherapy Regimen For NSCLC and TNBC Terminated USA 0
NCT03681951 Phase Ib/II GSK3145095 GSK3145095 + Pembrolizumab First-time-in-human (FTIH) Study of GSK3145095 Alone and in Combination With Other Anticancer Agents in Adults With Advanced Solid Tumors Terminated USA 0
NCT03694249 Phase II Ifetroban sodium Ifetroban in Treating Patients With Malignant Solid Tumors at High Risk of Metastatic Recurrence Active, not recruiting USA 0
NCT03700294 Phase I ADCT-601 Safety, Tolerability, Pharmacokinetics, and Antitumor Study of ADCT-601 to Treat Advanced Solid Tumors Terminated USA 0
NCT03709446 Phase Ib/II Leflunomide Leflunomide in Previously Treated Metastatic Triple Negative Cancers Recruiting USA 0
NCT03719326 Phase I Eganelisib + Etrumadenant + Pegylated liposomal doxorubicin Etrumadenant + Pegylated liposomal doxorubicin A Study to Evaluate Safety/Tolerability of Immunotherapy Combinations in Participants With Triple-Negative Breast Cancer or Gynecologic Malignancies Completed USA | AUS 0
NCT03733119 Phase II ONC201 ONC201 With and Without Methionine-Restricted Diet in Patients With Metastatic Triple Negative Breast Cancer Terminated USA 0
NCT03740893 Phase II Olaparib Ceralasertib Durvalumab PHOENIX DDR/Anti-PD-L1 Trial: A Pre-surgical Window of Opportunity and Post-surgical Adjuvant Biomarker Study of DNA Damage Response Inhibition and/or Anti-PD-L1 Immunotherapy in Patients With Neoadjuvant Chemotherapy Resistant Residual Triple Negative Breast Cancer (PHOENIX) Recruiting GBR 0
NCT03742102 Phase Ib/II Durvalumab + Oleclumab + Paclitaxel Durvalumab + Trastuzumab deruxtecan Durvalumab + Paclitaxel Capivasertib + Durvalumab + Paclitaxel A Study of Novel Anti-cancer Agents in Patients With Metastatic Triple Negative Breast Cancer (BEGONIA) Recruiting USA | GBR | CAN 3
NCT03742349 Phase I Canakinumab + Ieramilimab + Spartalizumab Ieramilimab + MCS110 + Spartalizumab Capmatinib + Ieramilimab + Spartalizumab Ieramilimab + Spartalizumab + Taminadenant Study of Safety and Efficacy of Novel Immunotherapy Combinations in Patients With Triple Negative Breast Cancer (TNBC). Terminated USA | ITA | ESP | AUS 5
NCT03752398 Phase I Izuralimab A Study of XmAb23104 in Subjects With Selected Advanced Solid Tumors (DUET-3) (DUET-3) Active, not recruiting USA 0
NCT03761914 Phase Ib/II Galinpepimut-S Galinpepimut-S + Pembrolizumab Pembrolizumab Sargramostim Galinpepimut-S in Combination With Pembrolizumab in Patients With Selected Advanced Cancers Unknown status USA 0
NCT03775850 Phase Ib/II EDP1503 EDP1503 + Pembrolizumab A Study of EDP1503 in Patients With Colorectal Cancer, Breast Cancer, and Checkpoint Inhibitor Relapsed Tumors Completed USA | CAN 0
NCT03797326 Phase II Lenvatinib + Pembrolizumab Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) in Previously Treated Participants With Select Solid Tumors (MK-7902-005/E7080-G000-224/LEAP-005) Active, not recruiting USA | ITA | GBR | FRA | ESP | DEU | CAN | AUS 9
NCT03800836 Phase I Atezolizumab + Ipatasertib + Paclitaxel Atezolizumab + Ipatasertib + Nab-paclitaxel A Study to Evaluate the Safety and Efficacy of Ipatasertib in Combination With Atezolizumab and Paclitaxel or Nab-Paclitaxel in Participants With Locally Advanced or Metastatic Triple-Negative Breast Cancer Completed USA | GBR | FRA | ESP | AUS 0
NCT03801369 Phase II Durvalumab + Olaparib Ceralasertib Olaparib + Selumetinib Capivasertib + Olaparib Olaparib in Combination With Either Durvalumab, Selumetinib, or Capivasertib or Ceralasertib Alone in Treating Patients With Metastatic Triple Negative Breast Cancer Recruiting USA 0
NCT03802604 Phase I Atezolizumab + Talimogene laherparepvec Combination of Talimogene Laherparepvec With Atezolizumab in Early Breast Cancer (PROMETEO) Active, not recruiting ESP 0
NCT03812393 Phase II Carboplatin + Neratinib + Paclitaxel Neratinib Evaluating the Efficacy of Neratinib on Live Cell HER2 Signaling Transduction Analysis Positive Triple Negative Breast (FACT-2) Active, not recruiting USA 0
NCT03815890 Phase II Nivolumab Ipilimumab + Nivolumab Pre-operative Trial for Breast Cancer With Nivolumab in Combination With Novel IO (BELLINI) Recruiting 1
NCT03818685 Phase II Ipilimumab + Nivolumab Capecitabine Evaluate the Clinical Benefit of a Post-operative Treatment Associating Radiotherapy + Nivolumab + Ipilimumab Versus Radiotherapy + Capecitabine for Triple Negative Breast Cancer Patients With Residual Disease (BreastImmune03) Active, not recruiting FRA 0
NCT03821935 Phase I ABBV-151 ABBV-151 + Budigalimab Study to Determine the Safety, Tolerability, Pharmacokinetics and RP2D of ABBV-151 as a Single Agent and in Combination With ABBV-181 in Participants With Locally Advanced or Metastatic Solid Tumors Recruiting USA | FRA | ESP | CAN | BEL | AUS 5
NCT03829501 Phase Ib/II Atezolizumab + KY1044 KY1044 Safety and Efficacy of KY1044 and Atezolizumab in Advanced Cancer Active, not recruiting USA | ITA | GBR 3
NCT03838367 Phase Ib/II Carboplatin + Leronlimab Leronlimab (PRO 140) Combined With Carboplatin in Patients With CCR5+ mTNBC Unknown status USA 0
NCT03849469 Phase I Pembrolizumab + XmAb22841 XmAb22841 A Study of XmAb22841 Monotherapy & in Combination w/ Pembrolizumab in Subjects w/ Selected Advanced Solid Tumors (DUET-4) Completed USA 0
NCT03853707 Phase Ib/II Carboplatin + Ipatasertib + Paclitaxel Carboplatin + Ipatasertib Atezolizumab + Capecitabine + Ipatasertib Ipatasertib in Combination With Carboplatin, Carboplatin/Paclitaxel, or Capecitabine/Atezolizumab in Treating Patients With Metastatic Triple Negative Breast Cancer Completed USA 0
NCT03861403 Phase Ib/II Avelumab + Cyclophosphamide + TRX518 A Dose Escalation and Expansion Study of TRX518 in Combination With Cyclophosphamide Plus Avelumab in Advanced Solid Tumors Terminated USA 0
NCT03872388 Phase II Atorvastatin + Capecitabine Capecitabine Atorvastatin in Treating Patients With Stage IIb-III Triple Negative Breast Cancer Who Did Not Achieve a Pathologic Complete Response After Receiving Neoadjuvant Chemotherapy Completed USA 0
NCT03872505 Phase II Carboplatin + Durvalumab + Paclitaxel Pre-operAtive Non-Anthracycline Chemotherapy, Durvalumab +/- RAdiation Therapy in Triple Negative Breast Cancer (PANDoRA) Withdrawn USA 0
NCT03875313 Phase Ib/II Talazoparib + Telaglenastat Study of CB-839 (Telaglenastat) in Combination With Talazoparib in Patients With Solid Tumors Terminated USA 0
NCT03891953 Phase I DKY709 DKY709 + Spartalizumab Study of Safety and Efficacy of DKY709 Alone or in Combination With PDR001 in Patients With Advanced Solid Tumors. Active, not recruiting USA | ESP | DEU 3
NCT03893955 Phase I ABBV-368 + ABBV-927 + Nab-paclitaxel ABBV-368 + ABBV-927 ABBV-368 + ABBV-927 + Budigalimab ABBV-927 + Budigalimab + Carboplatin ABBV-927 + Carboplatin ABBV-368 + ABBV-927 + Carboplatin A Study to Determine the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ABBV-927 With ABBV-368, Budigalimab (ABBV-181) and/or Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumors Active, not recruiting USA | FRA | ESP | AUS 2
NCT03901469 Phase II Talazoparib + ZEN-3694 A Study of ZEN003694 and Talazoparib in Patients With Triple Negative Breast Cancer (TNBC) Active, not recruiting USA | ESP | BEL 1
NCT03911453 Phase I Rucaparib Window of Opportunity Trial, PARP Inhibitor Rucaparib Affect on PD-L1 Expression in Triple Negative Breast Tumors Active, not recruiting USA 0
NCT03911973 Phase Ib/II Gedatolisib + Talazoparib Gedatolisib Plus Talazoparib in Advanced Triple Negative or BRCA1/2 Positive, HER2 Negative Breast Cancers Active, not recruiting USA 0
NCT03915678 Phase II Atezolizumab + BDB001 Atezolizumab Combined With BDB001 AnD Immunogenic Radiotherapy in Patients With Advanced Solid Tumors (AGADIR) Recruiting FRA 0
NCT03917381 Phase Ib/II GEN1046 GEN1046 Safety Trial in Patients With Malignant Solid Tumors Active, not recruiting USA | ITA | ESP 7
NCT03941730 Phase II Estradiol Estradiol in Treating Patients With ER Beta Positive, Triple Negative Locally Advanced or Metastatic Breast Cancer Enrolling by invitation USA 0
NCT03945721 Phase I Niraparib A Phase I Study of Niraparib Administered Concurrently With Postoperative RT in Triple Negative Breast Cancer Patients (UNITY) Recruiting USA 0
NCT03950570 Phase I ORIN1001 + Paclitaxel ORIN1001 ORIN1001 in Patients With Advanced Solid Tumors and Relapsed Refractory Metastatic Breast Cancer Active, not recruiting USA 0
NCT03952325 Phase II Pembrolizumab + Tesetaxel Nivolumab + Tesetaxel Tesetaxel Atezolizumab + Tesetaxel Tesetaxel Plus 3 Different PD-(L)1 Inhibitors in Patients With Metastatic TNBC and Tesetaxel Monotherapy in Patients With HER2 Negative MBC (CONTESSA TRIO) Terminated USA 2
NCT03961698 Phase II Atezolizumab + Bevacizumab + Eganelisib Atezolizumab + Eganelisib + Nab-paclitaxel Evaluation of IPI-549 Combined With Front-line Treatments in Pts. With Triple-Negative Breast Cancer or Renal Cell Carcinoma (MARIO-3) (MARIO-3) Active, not recruiting USA 0
NCT03971409 Phase II Avelumab + PF-04518600 Avelumab + Utomilumab Avelumab + Binimetinib Avelumab With Binimetinib, Utomilumab, or Anti-OX40 Antibody PF-04518600 in Treating Triple Negative Breast Cancer (InCITe) Recruiting USA 0
NCT03977467 Phase II Atezolizumab + Carboplatin Atezolizumab + Tiragolumab Atezolizumab + Cisplatin Atezolizumab + Bevacizumab + Carboplatin Atezolizumab + Bevacizumab + Cisplatin Atezolizumab and Tiragolumab in Patients With NSCLC or Advanced Solid Tumors Having Had Prior Treatment With a PD-1 Inhibitor Active, not recruiting USA 0
NCT03979508 Phase II Abemaciclib Abemaciclib in Treating Patients With Surgically Resectable, Chemotherapy Resistant, Triple Negative Breast Cancer Recruiting USA 0
NCT03990233 Phase I Effi-DEM Effi-DEM + Ezabenlimab A Trial of BI 765063 Monotherapy and in Combination With BI 754091 in Patients With Advanced Solid Tumours Active, not recruiting FRA | BEL 0
NCT03990896 Phase II Talazoparib Evaluation of Talazoparib, a PARP Inhibitor, in Patients With Somatic BRCA Mutant Metastatic Breast Cancer: Genotyping Based Clinical Trial Recruiting USA 0
NCT03992131 Phase Ib/II Lucitanib + Rucaparib Rucaparib + Sacituzumab govitecan-hziy A Study to Evaluate Rucaparib in Combination With Other Anticancer Agents in Patients With a Solid Tumor (SEASTAR) Terminated USA 0
NCT03997123 Phase III Paclitaxel Capivasertib + Paclitaxel Capivasertib+Paclitaxel as First Line Treatment for Patients With Locally Advanced or Metastatic TNBC (CapItello290) Active, not recruiting USA | GBR | FRA | ESP | CAN 25
NCT03997968 Phase Ib/II CYT01B A Phase 1/2 Study of CYT-0851, an Oral RAD51 Inhibitor, in B-Cell Malignancies and Advanced Solid Tumors Active, not recruiting USA 0
NCT04024436 Phase II Fulvestrant + Futibatinib Futibatinib A Study of TAS-120 in Patients With Metastatic Breast Cancer Active, not recruiting USA | ITA | GBR | FRA | ESP | CAN 1
NCT04024800 Phase II AE37 + Pembrolizumab Establishing the Recommended Biological Dose for AE37 Peptide Vaccine in Combination With Pembrolizumab That Will Enhance the Tumor-specific Immune Response and Demonstrate Efficacy in Patients With Advanced Triple-negative Breast Cancer (NSABP FB-14) Active, not recruiting USA 0
NCT04032080 Phase II Prexasertib LY3023414 Treatment With Oral LY3023414 To Inhibit Homologous Recombination Followed By Prexasertib (ExIST) Completed USA 0
NCT04039230 Phase Ib/II Sacituzumab govitecan-hziy + Talazoparib Study to Evaluate Sacituzumab Govitecan in Combination With Talazoparib in Patients With Metastatic Breast Cancer. Recruiting USA 0
NCT04041128 Phase I Olaparib PARP Inhibition During Pre-surgical Window in Breast/Ovary Cancer Completed USA 0
NCT04052555 Phase I Berzosertib Testing the Addition of an Anti-cancer Drug, Berzosertib, to the Usual Treatment (Radiation Therapy) for Chemotherapy-Resistant Triple-Negative and Estrogen and/or Progesterone Receptor Positive, HER2 Negative Breast Cancer Active, not recruiting USA 0
NCT04060342 Phase Ib/II GB1275 GB1275 + Pembrolizumab GB1275 + Gemcitabine + Nab-paclitaxel GB1275 Monotherapy and in Combination With an Anti-PD1 Antibody in Patients With Specified Advanced Solid Tumors or in Combination With Standard of Care in Patients With Metastatic Pancreatic Adenocarcinoma Terminated USA | GBR 0
NCT04081389 Phase I Celecoxib + Cyclophosphamide + Doxorubicin + Interferon alpha-2b + Paclitaxel + Rintatolimod Chemokine Modulation Therapy and Standard Chemotherapy Before Surgery for the Treatment of Early Stage Triple Negative Breast Cancer Completed USA 0
NCT04095689 Phase II Cyclophosphamide + Docetaxel + Doxorubicin + IL-12 gene + L-NMMA + Pembrolizumab TAC Chemotherapy and Pembrolizumab Plus Interleukin-12 Gene Therapy and L-NMMA in Triple Negative Breast Cancer Suspended USA 0
NCT04096638 Phase I Nivolumab + SB 11285 SB 11285 Evaluating Safety and Efficacy of SB 11285 Alone and in Combination With Nivolumab in Patients With Advanced Solid Tumors Recruiting USA 0
NCT04102618 Phase I Atezolizumab + Pelareorep Atezolizumab + Pelareorep + Trastuzumab Letrozole + Pelareorep Atezolizumab + Letrozole + Pelareorep A Window-of-opportunity Study of Pelareorep in Early Breast Cancer (AWARE-1) Terminated ESP 0
NCT04111510 Phase II LN-145 Autologous Tumor Infiltrating Lymphocytes in Patients With Pretreated Metastatic Triple Negative Breast Cancer Completed USA 0
NCT04115306 Phase I PMD-026 Phase 1/1b Study of Oral PMD-026 in Patients With Metastatic Breast Cancer and Metastatic Triple Negative Breast Cancer Active, not recruiting USA 0
NCT04123704 Phase II Sitravatinib Sitravatinib in Metastatic Breast Cancer Withdrawn USA 0
NCT04148911 Phase III Atezolizumab + Nab-paclitaxel A Study of Atezolizumab Plus Nab-Paclitaxel in the Treatment of Unresectable Locally Advanced or Metastatic PD-L1-Positive Triple-Negative Breast Cancer (EL1SSAR) Active, not recruiting ITA | FRA | ESP 10
NCT04152499 Phase Ib/II SKB264 Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies (A264) Recruiting USA 1
NCT04159818 Phase II Nivolumab Doxorubicin + Nivolumab Cisplatin + Nivolumab Immune Induction Strategies to Improve Response to Immune Checkpoint Blockade in Triple Negative Breast Cancer (TNBC) Patients (TONIC-2) Recruiting 1
NCT04176848 Phase II CFI-400945 + Durvalumab CFI-400945 and Durvalumab in Patients With Advanced Triple Negative Breast Cancer Unknown status CAN 0
NCT04177108 Phase III Ipatasertib + Paclitaxel Atezolizumab + Paclitaxel Atezolizumab + Ipatasertib + Paclitaxel Paclitaxel A Study Of Ipatasertib in Combination With Atezolizumab and Paclitaxel as a Treatment for Participants With Locally Advanced or Metastatic Triple-Negative Breast Cancer. Completed USA | ITA | GBR | FRA | ESP | CAN | BEL | AUT | AUS 28
NCT04185311 Phase I Ipilimumab + Nivolumab + Talimogene laherparepvec Ipilimumab, Nivolumab, and Talimogene Laherparepvec Before Surgery in Treating Participants With Localized, Triple-Negative or Estrogen Receptor Positive, HER2 Negative Breast Cancer-deleted Terminated USA 0
NCT04191135 Phase II Carboplatin + Gemcitabine + Pembrolizumab Carboplatin + Gemcitabine + Olaparib + Pembrolizumab Study of Olaparib Plus Pembrolizumab Versus Chemotherapy Plus Pembrolizumab After Induction With First-Line Chemotherapy Plus Pembrolizumab in Triple Negative Breast Cancer (TNBC) (MK-7339-009/KEYLYNK-009) Active, not recruiting USA | GBR | FRA | ESP | DEU | CAN 9
NCT04216472 Phase II Alpelisib + Nab-paclitaxel Nab-paclitaxel and Alpelisib for the Treatment of Anthracycline Refractory Triple Negative Breast Cancer With PIK3CA or PTEN Alterations Active, not recruiting USA 0
NCT04225117 Phase II Enfortumab vedotin-ejfv A Study to Evaluate Enfortumab Vedotin in Subjects With Locally Advanced or Metastatic Malignant Solid Tumors (EV-202) Recruiting USA | CAN 1
NCT04230109 Phase II Sacituzumab govitecan-hziy Sacituzumab Govitecan In TNBC (NeoSTAR) Recruiting USA 0
NCT04243616 Phase II Carboplatin + Cemiplimab + Cyclophosphamide + Doxorubicin + Paclitaxel Cemiplimab + Cyclophosphamide + Doxorubicin + Paclitaxel Cemiplimab in High Risk or Locally Advanced Hormone Receptor Positive HER2 Negative or Triple-Negative Breast Cancer Recruiting USA 0
NCT04249167 Phase I Atezolizumab + Nab-paclitaxel Cryoablation, Atezolizumab/Nab-paclitaxel for Locally Advanced or Metastatic Triple Negative Breast Cancer Withdrawn 0
NCT04251533 Phase III Alpelisib + Nab-paclitaxel Nab-paclitaxel Study Assessing the Efficacy and Safety of Alpelisib + Nab-paclitaxel in Subjects With Advanced TNBC Who Carry Either a PIK3CA Mutation or Have PTEN Loss (EPIK-B3) Active, not recruiting USA | ITA | GBR | FRA | ESP | DEU | AUT | AUS 22
NCT04260802 Phase Ib/II OC-001 + unspecified PD-L1 antibody OC-001 + unspecified PD-1 antibody OC-001 A Study to Evaluate the Safety and Pharmacokinetics of OC-001 in Patients With Locally Advanced or Metastatic Cancers Recruiting CAN 0
NCT04265872 Phase I Bortezomib + Cisplatin + Pembrolizumab Bortezomib Followed by Pembrolizumab and Cisplatin in metTNBC Recruiting USA 0
NCT04282018 Phase Ib/II BGB-10188 + Zanubrutinib BGB-10188 + Tislelizumab BGB-10188 Study of BGB-10188 as Monotherapy, and in Combination With Zanubrutinib, and Tislelizumab Recruiting AUS 1
NCT04282044 Phase I CRX100 Study of CRX100 in Patients With Advanced Solid Tumors Recruiting USA 0
NCT04300556 Phase Ib/II MORAb-202 A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRa)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types Recruiting USA | GBR | FRA | ESP 0
NCT04315233 Phase I Belinostat + Ribociclib Ribociclib&Belinostat In Patients w Metastatic Triple Neg Breast Cancer & Recurrent Ovarian Cancer w Response Prediction By Genomics (CHARGE) Recruiting USA 0
NCT04331067 Phase Ib/II Cabiralizumab + Carboplatin + Nivolumab + Paclitaxel Carboplatin + Nivolumab + Paclitaxel Cabiralizumab in Combination With Nivolumab and Neoadjuvant Chemotherapy in Patients With Localized Triple-negative Breast Cancer Active, not recruiting USA 0
NCT04332653 Phase Ib/II NT-I7 + Pembrolizumab NT-I7 (Efineptakin Alfa) in Combination With Pembrolizumab in Participants With Advanced Solid Tumors Active, not recruiting USA 0
NCT04333706 Phase Ib/II Capecitabine Capecitabine + Sarilumab A Dose Finding Phase 1 of Sarilumab Plus Capecitabine in HER2/Neu-Negative Metastatic Breast Cancer and a Single-arm, Historically-controlled Phase 2 Study of Sarilumab Plus Capecitabine in Stage I-III Triple Negative Breast Cancer With High-Risk Residual Disease (EMPOWER) (EMPOWER) Recruiting USA 0
NCT04338685 Phase I RO7119929 + Tocilizumab A Study Evaluating Safety, Pharmacokinetics, Pharmacodynamics, And Clinical Activity Of RO7119929 (TLR7 Agonist) In Participants With Unresectable Advanced Or Metastatic Hepatocellular Carcinoma, Biliary Tract Cancer, Or Solid Tumors With Hepatic Metastases Completed USA | ESP 4
NCT04344795 Phase I TPST-1495 Pembrolizumab + TPST-1495 Phase 1a/1b Study of TPST-1495 Alone and With Pembrolizumab in Subjects With Solid Tumors Recruiting USA 0
NCT04345913 Phase Ib/II Eribulin Copanlisib + Eribulin Testing the Addition of Copanlisib to Eribulin for the Treatment of Advanced-Stage Triple Negative Breast Cancer Active, not recruiting USA 0
NCT04348747 Phase II Anti-HER2/HER3 DC vaccine + Celecoxib + Interferon alpha-2b + Pembrolizumab + Rintatolimod Anti-HER2/HER3 DC vaccine + Celecoxib + Interferon alpha-2b + Rintatolimod Dendritic Cell Vaccines Against Her2/Her3, Cytokine Modulation Regimen, and Pembrolizumab for the Treatment of Brain Metastasis From Triple Negative Breast Cancer or HER2+ Breast Cancer Recruiting USA 0
NCT04360941 Phase I Avelumab + Palbociclib PAveMenT: Palbociclib and Avelumab in Metastatic AR+ Triple Negative Breast Cancer (PAveMenT) Recruiting GBR 0
NCT04373031 Phase II Cyclophosphamide + Doxorubicin + Paclitaxel + Pembrolizumab Cyclophosphamide + Doxorubicin + IRX-2 + Paclitaxel + Pembrolizumab Pembrolizumab, IRX-2, and Chemotherapy in Triple Negative Breast Cancer Active, not recruiting USA 0
NCT04408118 Phase II Atezolizumab + Bevacizumab + Paclitaxel First Line Atezolizumab, Paclitaxel, and Bevacizumab (Avastin) in mTNBC (ATRACTIB) Completed ITA | GBR | FRA | ESP | DEU 0
NCT04423029 Phase Ib/II DF6002 DF6002 + Nivolumab A Study to Assess DF6002 (BMS-986415) Alone and in Combination With Nivolumab in Participants With Locally Advanced or Metastatic Solid Tumors Recruiting USA | FRA | ESP | AUS 0
NCT04424641 Phase Ib/II GEN1044 A Study on the Safety of GEN1044 (DuoBody-CD3x5T4) in Subjects With Malignant Solid Tumors Terminated USA | ESP 2
NCT04427293 Phase I Lenvatinib + Pembrolizumab Preoperative Lenvatinib Plus Pembrolizumab in Early-Stage Triple-Negative Breast Cancer (TNBC) Recruiting USA 0
NCT04429542 Phase I BCA101 BCA101 + Pembrolizumab Study of Safety and Tolerability of BCA101 Monotherapy and in Combination Therapy in Patients With EGFR-driven Advanced Solid Tumors Recruiting USA | CAN 0
NCT04432857 Phase I E7046 + Pembrolizumab AN0025 and Pembrolizumab Combination in Advanced Solid Tumors Active, not recruiting USA | FRA 0
NCT04434040 Phase II Atezolizumab + Ipatasertib Ipatasertib + Atezolizumab to Prevent Recurrence in TNBC Active, not recruiting USA 0
NCT04434482 Phase I Senaparib + Temozolomide IMP4297 in Combination With Temozolomide in Patients With Advanced Solid Tumors and Small Cell Lung Cancer Recruiting USA | AUS 3
NCT04434560 Phase II Ipilimumab + Nivolumab Neoadjuvant Immunotherapy in Brain Metastases Terminated USA 0
NCT04441099 Phase Ib/II NBE-002 NBE-002 in Patients With Advanced Solid Tumors Terminated USA 0
NCT04443348 Phase II Pembrolizumab Cyclophosphamide + Doxorubicin + Paclitaxel + Pembrolizumab Carboplatin + Cyclophosphamide + Doxorubicin + Paclitaxel + Pembrolizumab Pre-op Pembro + Radiation Therapy in Breast Cancer (P-RAD) Recruiting USA 0
NCT04445844 Phase II Pelareorep + Retifanlimab INCMGA00012 and Pelareorep for the Treatment of Metastatic Triple Negative Breast Cancer, IRENE Study Recruiting USA 0
NCT04454528 Phase Ib/II Pembrolizumab BreastVax: Radiation Boost to Enhance Effectiveness of Immune Checkpoint Blockade Therapy in Operable Breast Cancer Recruiting USA 0
NCT04461600 Phase II BMS-906024 A Study of AL101 Monotherapy in Patients With Notch Activated Triple Negative Breast Cancer (TENACITY) Terminated USA | GBR | ESP | BEL 1
NCT04464174 Phase II Eribulin + Ipatasertib Capecitabine + Ipatasertib Carboplatin + Gemcitabine + Ipatasertib Ipatasertib Plus Non-Taxane Chemotherapy for Advanced or Metastatic Triple-Negative Breast Cancer (PATHFINDER) Completed ESP 1
NCT04468061 Phase II Sacituzumab govitecan-hziy Pembrolizumab + Sacituzumab govitecan-hziy Sacituzumab Govitecan +/- Pembrolizumab in Metastatic TNBC Recruiting USA 0
NCT04489940 Phase II Bintrafusp alfa Bintrafusp Alfa in High Mobility Group AT-Hook 2 (HMGA2) Expressing Triple Negative Breast Cancer Terminated USA | ITA | FRA | ESP | BEL 1
NCT04491942 Phase I BAY1895344 + Cisplatin BAY1895344 + Cisplatin + Gemcitabine Testing the Addition of an Anti-cancer Drug, BAY 1895344, to the Usual Chemotherapy Treatment (Cisplatin, or Cisplatin and Gemcitabine) for Advanced Solid Tumors With Emphasis on Urothelial Cancer Active, not recruiting USA | CAN 0
NCT04494958 Phase Ib/II Binimetinib + Palbociclib Palbociclib and Binimetinib in Advanced Triple Negative Breast Cancer (PALBOBIN) Completed ESP 0
NCT04504669 Phase I AZD8701 + Durvalumab AZD8701 First Time in Human Study of AZD8701 With or Without Durvalumab in Participants With Advanced Solid Tumours Active, not recruiting USA | FRA | ESP | CAN 0
NCT04514484 Phase I Cabozantinib + Nivolumab Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV Active, not recruiting USA 0
NCT04521413 Phase Ib/II CFI-402411 + Pembrolizumab CFI-402411 Safety and Efficacy Study of CFI-402411 in Subjects With Advanced Solid Malignancies Recruiting USA | CAN 1
NCT04521621 Phase Ib/II Coxsackievirus A21 + Pembrolizumab A Study of Gebasaxturev (V937) in Combination With Pembrolizumab (MK-3475) in Participants With Advanced/Metastatic Solid Tumors (V937-013) Completed USA | ITA | FRA | ESP | DEU | CAN 8
NCT04553133 Phase II PF-07104091 Letrozole + Palbociclib + PF-07104091 Palbociclib + PF-07104091 PF-07104091 as a Single Agent and in Combination Therapy Recruiting USA 3
NCT04561362 Phase Ib/II BT8009 BT8009 + Pembrolizumab Study BT8009-100 in Subjects With Nectin-4 Expressing Advanced Malignancies Recruiting USA | ITA | GBR | FRA | ESP | CAN 0
NCT04574583 Phase Ib/II Bintrafusp alfa + FPV-CV301 + MVA-BN-CV301 + SX-682 Phase I/II Trial Investigating the Safety, Tolerability, Pharmacokinetics, Immune and Clinical Activity of SX-682 in Combination With BinTrafusp Alfa (M7824 or TGF-beta "Trap"/PD-L1) With CV301 TRICOM in Advanced Solid Tumors (STAT) Active, not recruiting USA 0
NCT04577963 Phase Ib/II Fruquintinib + Tislelizumab A Study of Fruquintinib in Combination With Tislelizumab in Advanced Triple Negative Breast Cancer Active, not recruiting USA 0
NCT04580485 Phase I INCB106385 + Retifanlimab INCB106385 INCB106385 Alone or in Combination With Immunotherapy in Advanced Solid Tumors Completed USA | ITA | GBR | FRA | ESP | BEL 0
NCT04584112 Phase I Atezolizumab + Cyclophosphamide + Doxorubicin + Pegfilgrastim + Tiragolumab Atezolizumab + Cyclophosphamide + Doxorubicin + Sargramostim + Tiragolumab Atezolizumab + Nab-paclitaxel + Tiragolumab Atezolizumab + Cyclophosphamide + Doxorubicin + Filgrastim + Tiragolumab A Study of the Safety, Efficacy, and Pharmacokinetics of Tiragolumab in Combination With Atezolizumab and Chemotherapy in Participants With Triple-Negative Breast Cancer Completed USA | ESP | DEU | AUS 4
NCT04592653 Phase Ib/II ALKS 4230 ALKS 4230 + Pembrolizumab Less Frequent IV Dosing & Tumor Microenvironment (TME) Study of Nemvaleukin Alfa (ALKS 4230) Monotherapy and in Combination With Pembrolizumab (ARTISTRY-3) (ARTISTRY-3) Recruiting USA | ESP 0
NCT04596150 Phase II CX-2009 CX-072 + CX-2009 Study to Evaluate the Safety and Antitumor Activity of CX-2009 Monotherapy and in Combination With CX-072 in Advanced Breast Cancer Completed USA | ESP 1
NCT04622774 Phase I IMGC936 First-in-Human Study of IMGC936 in Patients With Advanced Solid Tumors Completed USA | ITA | ESP 0
NCT04639245 Phase Ib/II MAGE-A1-specific TCR cells + unspecified PD-1 antibody Cyclophosphamide + Fludarabine Atezolizumab + MAGE-A1-specific TCR cells MAGE-A1-specific TCR cells Genetically Engineered Cells (MAGE-A1-specific T Cell Receptor-transduced Autologous T-cells) and Atezolizumab for the Treatment of Metastatic Triple Negative Breast Cancer, Urothelial Cancer, or Non-small Cell Lung Cancer Terminated USA 0
NCT04682431 Phase I Pembrolizumab + PY159 PY159 A Phase 1a/1b FIH Study of PY159 and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors Active, not recruiting USA 0
NCT04683679 Phase II Olaparib + Pembrolizumab Pembrolizumab A Study of Radiation Therapy With Pembrolizumab and Olaparib or Other Radiosensitizers in Women Who Have Triple-Negative or Hormone-Receptor Positive/Her2 Negative Breast Cancer Recruiting USA 0
NCT04690855 Phase II Atezolizumab + Talazoparib A Study to Evaluate TAlazoparib, Radiotherapy and Atezolizumab in gBRCA 1/2 Negative Patients With PD-L1+ Metastatic Triple Negative Breast Cancer (TARA) Terminated USA 0
NCT04691375 Phase I Pembrolizumab + PY314 PY314 A Study of PY314 in Subjects With Advanced Solid Tumors Active, not recruiting USA 0
NCT04699630 Phase II Patritumab deruxtecan A Study of U3-1402 (Patritumab Deruxtecan) in Subjects With Metastatic Breast Cancer Recruiting USA 0
NCT04706962 Phase I TH1902 TH1902 in Patients With Advanced Solid Tumors Recruiting USA | CAN 0
NCT04711824 Phase Ib/II Nab-paclitaxel Carboplatin + Gemcitabine Cisplatin Durvalumab + Olaparib Paclitaxel Capecitabine Gemcitabine Carboplatin Eribulin Study of Stereotactic Radiosurgery With Olaparib Followed by Durvalumab and Physician's Choice Systemic Therapy in Subjects With Breast Cancer Brain Metastases (SOLARA) Recruiting USA 0
NCT04725331 Phase Ib/II BT-001 BT-001 + Pembrolizumab A Clinical Trial Assessing BT-001 Alone and in Combination With Pembrolizumab in Metastatic or Advanced Solid Tumors Recruiting FRA | BEL 0
NCT04726332 Phase I Abiraterone + Prednisone + XL102 Fulvestrant + XL102 XL102 Study of XL102 as Single-Agent and Combination Therapy in Subjects With Solid Tumors (QUARTZ-101) Active, not recruiting USA 0
NCT04739670 Phase II Atezolizumab + Bevacizumab + Carboplatin + Gemcitabine Evaluating the Efficacy and Safety of Bevacizumab, Carboplatin, Gemcitabine and Atezolizumab in Breast Cancer (BELLA) Recruiting AUS 0
NCT04762901 Phase I Cyclophosphamide + Doxorubicin + Niraparib + Pegfilgrastim Cyclophosphamide + Doxorubicin + Niraparib Niraparib + Paclitaxel Carboplatin + Niraparib + Paclitaxel LCI-BRE-MTN-NIR-001:Ph I Study of Niraparib in Combo With Standard Chemo in Metastatic Trip Neg Breast Cancer Withdrawn 0
NCT04770272 Phase II Atezolizumab + Carboplatin + Paclitaxel Atezolizumab + Cyclophosphamide + Epirubicin Atezolizumab Study to Compare a Mono Atezolizumab Window Followed by a Atezolizumab - CTX Therapy With Atezolizumab - CTX Therapy (neoMono) Active, not recruiting DEU 0
NCT04787042 Phase Ib/II Pembrolizumab + ST-067 ST-067 Obinutuzumab + ST-067 Phase 1a and Phase 2 Study for Safety, Preliminary Efficacy, PK and PD of ST-067 Recruiting USA 0
NCT04789668 Phase Ib/II Bintrafusp alfa + Pimasertib Bintrafusp Alfa and Pimasertib for the Treatment of Patients With Brain Metastases Completed USA 0
NCT04799249 Phase III Carboplatin + Gemcitabine Carboplatin + Gemcitabine + Trilaciclib Trilaciclib, a CDK 4/6 Inhibitor, in Patients Receiving Gemcitabine and Carboplatin for Metastatic Triple-Negative Breast Cancer (TNBC) (PRESERVE 2) Active, not recruiting USA | FRA | ESP | AUS 7
NCT04808362 Phase Ib/II OMO-103 Phase 1/2 Study to Evaluate Safety, PK and Efficacy of the MYC-Inhibitor OMO-103 in Solid Tumours (MYCure) Active, not recruiting ESP 0
NCT04837209 Phase II Dostarlimab-gxly + Niraparib Radiation, Immunotherapy and PARP Inhibitor in Triple Negative Breast Cancer (NADiR) Recruiting USA 0
NCT04837677 Phase I PRT1419 A Study of PRT1419 in Patients With Advanced Solid Tumors Completed USA 0
NCT04849364 Phase II Capecitabine + Inavolisib Atezolizumab + Capecitabine Capecitabine + Talazoparib Capecitabine Atezolizumab + Capecitabine + Talazoparib Circulating Tumor DNA Enriched, Genomically Directed Post-neoadjuvant Trial for Patients With Residual Triple Negative Breast Cancer (PERSEVERE) Recruiting USA 0
NCT04878484 Phase I TCRT-ESO-A2 Evaluate TCRT-ESO-A2 Autologous T Cells Expressing TCR Specific for NY-ESO-1 in Subjects With Advanced Solid Tumors Withdrawn 0
NCT04879849 Phase I Pembrolizumab + TAK-676 A Study of TAK-676 With Pembrolizumab After Radiation Therapy to Treat a Number of Cancers Active, not recruiting USA 0
NCT04915755 Phase III Niraparib Efficacy and Safety Comparison of Niraparib to Placebo in Participants With Human Epidermal Growth Factor 2 Negative (HER2-) Breast Cancer Susceptibility Gene Mutation (BRCAmut) or Triple-Negative Breast Cancer (TNBC) With Molecular Disease (ZEST) Active, not recruiting USA | ITA | GBR | FRA | ESP | DEU | CAN | BEL | AUT | AUS 18
NCT04916002 Phase II Cemiplimab + Vidutolimod CMP-001 in Combination With IV PD-1-Blocking Antibody in Subjects With Certain Types of Advanced or Metastatic Cancer Recruiting USA | AUS 0
NCT04925284 Phase I XB002 Nivolumab + XB002 Study of XB002 in Subjects With Solid Tumors (JEWEL-101) Recruiting USA | ITA | GBR | FRA | ESP | BEL | AUS 1
NCT04927884 Phase Ib/II ALT-803 + Cyclophosphamide + PD-L1.t-haNK cells + Sacituzumab govitecan-hziy A Study of Sacituzumab With Chemoimmunotherapy to Treat Advanced Triple-Negative Breast Cancer After Prior Therapies Terminated USA 0
NCT04947189 Phase Ib/II Dexamethasone + Docetaxel + Seviteronel Seviteronel in Combination With Chemotherapy in Androgen-receptor Positive Metastatic Triple-negative Breast Cancer (4CAST) Recruiting AUS 0
NCT04958785 Phase II Hu5F9-G4 + Nab-paclitaxel Hu5F9-G4 + Sacituzumab govitecan-hziy Nab-paclitaxel Paclitaxel Hu5F9-G4 + Paclitaxel Study of Magrolimab Combination Therapy in Patients With Non-Surgically Removable Locally Advanced or Metastatic Triple-Negative Breast Cancer (ELEVATE TNBC) Active, not recruiting USA | GBR | AUS 3
NCT04972981 Phase I ADCT-901 A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of ADCT-901 in Participants With Selected Advanced Solid Tumors Active, not recruiting USA | GBR | ESP 0
NCT04986852 Phase II Pembrolizumab + Tanibirumab Olinvacimab With Pembrolizumab in Patients With mTNBC Recruiting AUS 0
NCT04992013 Phase II Niraparib Niraparib in Tumors Metastatic to the CNS Recruiting USA 0
NCT05001282 Phase Ib/II ELU001 A Study to Evaluate ELU001 in Patients With Solid Tumors That Overexpress Folate Receptor Alpha (FRalpha) Recruiting USA 0
NCT05001347 Phase II Uliledlimab A Clinical Study of TJ004309 With Atezolizumab (TECENTRIQ) in Patients With Ovarian Cancer and Selected Solid Tumors Completed USA 0
NCT05006794 Phase I GS-9716 + Sacituzumab govitecan-hziy GS-9716 Docetaxel + GS-9716 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of GS-9716 as Monotherapy and in Combination With Anticancer Therapies in Adults With Solid Malignancies Recruiting USA 1
NCT05007106 Phase II MK-7684A + Paclitaxel Cisplatin + Fluorouracil + MK-7684A Pembrolizumab Lenvatinib + MK-7684A MK-7684A MK-7684A With or Without Other Anticancer Therapies in Participants With Selected Solid Tumors (MK-7684A-005) Recruiting USA | ITA | FRA | ESP | DEU | CAN 9
NCT05020860 Phase II Cyclophosphamide + Doxorubicin + Paclitaxel Carboplatin + Cyclophosphamide + Doxorubicin + Paclitaxel Carboplatin + Cyclophosphamide + Doxorubicin + Paclitaxel + Pembrolizumab Cyclophosphamide + Doxorubicin + Paclitaxel + Pertuzumab + Trastuzumab Correlation of Clinical Response to Pathologic Response in Patients With Early Breast Cancer (RESPONSE) Recruiting USA 0
NCT05029999 Phase I CDX-1140 + CDX-301 + Pegylated liposomal doxorubicin CD40 Agonist, Flt3 Ligand, and Chemotherapy in Triple Negative Breast Cancer Recruiting USA 0
NCT05043714 Phase I NG-641 + Nivolumab Study of NG-641 in Combination With Nivolumab in Metastatic or Advanced Epithelial Tumours (NEBULA) Recruiting USA | GBR 0
NCT05052255 Phase Ib/II RVU120 RVU120 (SEL120) in Patients With Relapse/Refractory Metastatic or Advanced Solid Tumors Recruiting ESP 1
NCT05057013 Phase Ib/II HMBD-001 HMBD-001 in Advanced HER3 Positive Solid Tumours Recruiting GBR 0
NCT05064280 Phase II Lenvatinib Pembrolizumab Phase II Study of Pembrolizumab in Combination With Lenvatinib in Patients With TNBC, NSCLC, and Other Tumor Types and Brain Metastases Recruiting USA 0
NCT05067972 Phase I PF-07260437 A Study of PF-07260437 in Advanced or Metastatic Solid Tumors (C4431001) Terminated USA 1
NCT05069935 Phase I Atezolizumab + FT538 Cetuximab + FT538 FT538 + Trastuzumab FT538 + Pembrolizumab FT538 + Nivolumab Avelumab + FT538 Cyclophosphamide + Fludarabine FT538 in Combination With Monoclonal Antibodies in Advanced Solid Tumors Terminated USA 0
NCT05070247 Phase I TAK-500 Pembrolizumab + TAK-500 A Study of TAK-500 With or Without Pembrolizumab in Adults With Select Locally Advanced or Metastatic Solid Tumors Recruiting USA 0
NCT05076760 Phase I MEM-288 Study of MEM-288 Oncolytic Virus in Solid Tumors Including Non-Small Cell Lung Cancer (NSCLC) Recruiting USA 0
NCT05082259 Phase I ASTX-660 + Pembrolizumab ASTEROID: A Trial of ASTX660 in Combination With Pembrolizumab (ASTEROID) Recruiting GBR 0
NCT05082610 Phase I HMBD-002 HMBD-002 + Pembrolizumab A Study of HMBD-002, a Monoclonal Antibody Targeting VISTA, as Monotherapy and Combined With Pembrolizumab Recruiting USA 0
NCT05086692 Phase Ib/II MDNA11 + Pembrolizumab A Beta-only IL-2 ImmunoTherapY Study (ABILITY-1) Recruiting USA | CAN | AUS 1
NCT05093387 Phase I Carboplatin + Pembrolizumab + SGT-53 SGT-53, Carboplatin, and Pembrolizumab for the Treatment of Metastatic Triple Negative Inflammatory Breast Cancer Withdrawn USA 0
NCT05094804 Phase Ib/II Nivolumab + OR2805 OR2805 + Pembrolizumab OR2805 A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With a PD-1 Inhibitor Recruiting USA 0
NCT05095207 Phase Ib/II Abemaciclib + Bicalutamide Abemaciclib in Combination With Bicalutamide for Androgen Receptor-positive, HER2-negative Metastatic Breast Cancer Recruiting USA 0
NCT05101070 Phase Ib/II Pembrolizumab + S-531011 Pembrolizumab S-531011 S-531011 as Monotherapy and in Combination With an Immune Checkpoint Inhibitor in Advanced or Metastatic Solid Tumors (aCCeleR8-001) Recruiting USA 1
NCT05107674 Phase I NX-1607 A Study of NX-1607 in Adults With Advanced Malignancies Recruiting USA | GBR 0
NCT05111561 Phase I Binimetinib + ZEN-3694 Testing the Combination of the Anticancer Drugs ZEN003694 and Binimetinib in Patients With Advanced/Metastatic or Unresectable Solid Tumors With RAS Alterations and Triple Negative Breast Cancer Recruiting USA 0
NCT05112536 Phase II Cyclophosphamide + Doxorubicin + Pembrolizumab + Trilaciclib Carboplatin + Paclitaxel + Trilaciclib Trilaciclib Trilaciclib, a CDK4/6 Inhibitor, in Patients With Early-Stage Triple Negative Breast Cancer Completed USA 0
NCT05113966 Phase II Sacituzumab govitecan-hziy + Trilaciclib Trilaciclib in Patients Receiving Sacituzumab Govitecan-hziy for Triple Negative Breast Cancer Active, not recruiting USA 0
NCT05123482 Phase Ib/II AZD8205 First in Human Study to Evaluate AZD8205 in Patients With Advanced or Metastatic Solid Malignancies Recruiting USA | GBR | ESP | CAN | BEL | AUS 8
NCT05128734 Phase II Olaparib + Temozolomide Temozolomide Temozolomide Monotherapy or in Combination With Olaparib in Patients With Triple Negative Breast Cancer (TNBC) Not yet recruiting CAN 0
NCT05142592 Phase I IPG7236 IPG7236 in Patients With Advanced Solid Tumors Unknown status USA 0
NCT05143229 Phase I Alpelisib + Sacituzumab govitecan-hziy Alpelisib And Sacituzumab Govitecan For Treatment Of Breast Cancer (ASSET) Recruiting USA 0
NCT05144698 Phase II RAPA-201 RAPA-201 Therapy of Solid Tumors Recruiting USA 0
NCT05177796 Phase II Carboplatin + Cyclophosphamide + Doxorubicin + Paclitaxel + Panitumumab + Pembrolizumab Anti-EGFR and Immunotherapy for TN-IBC (TN-IBC) Withdrawn USA 0
NCT05180006 Phase II Atezolizumab Atezolizumab + Pertuzumab + Trastuzumab Atezolizumab + Ipatasertib Atezolizumab + Bevacizumab Impact of Neoadjuvant Immunotherapy in Early Stage Breast Cancer Before Standard Therapy (BIS-Program) Recruiting FRA 0
NCT05181462 Phase Ib/II Carboplatin + Gemcitabine Carboplatin + Gemcitabine + Nidanilimab Nadunolimab in Combination With Gemcitabine Plus Carboplatin in Patients With Advanced Triple Negative Breast Cancer. (TRIFOUR) Recruiting ESP 0
NCT05194072 Phase I SGN-B7H4V A Study of SGN-B7H4V in Advanced Solid Tumors Recruiting USA | ITA | GBR | ESP | DEU | CAN 0
NCT05198843 Phase Ib/II Dasatinib + Icosapent Ethyl Testing an Omega-3 Fatty Acid-Based Anti-Cancer Therapy for Patients With Triple-Negative Inflammatory Breast Cancer That Has Spread to Other Parts of the Body Terminated USA 0
NCT05203445 Phase II Olaparib + Pembrolizumab A Study of Olaparib and Pembrolizumab in People With Triple Negative Breast Cancer (TNBC) or Hormone Receptor-positive HER2-negative Breast Cancer Recruiting USA 0
NCT05215106 Phase II Durvalumab Short-term Pre-OPerative Durvalumab (MEDI 4736) in Early Small Triple Negative Breast Cancer Patients (POP-Durva) (POP-DURVA) Recruiting FRA 0
NCT05233696 Phase II Nab-paclitaxel + Pembrolizumab Paclitaxel + Pembrolizumab Radiotherapy in Combo With Chemo and Immunotherapy in Patients With PD-L1 Positive Metastatic TNBC Withdrawn USA 0
NCT05252390 Phase Ib/II NUV-868 NUV-868 + Olaparib Enzalutamide + NUV-868 NUV-868 as Monotherapy and in Combination With Olaparib or Enzalutamide in Adult Patients With Advanced Solid Tumors Recruiting USA | AUS 0
NCT05255666 Phase II Liposomal irinotecan + Pembrolizumab Combination Liposomal Irinotecan and Pembrolizumab For Triple-Negative Breast Cancer (TNBC) With Brain Metastases (BM) Withdrawn 0
NCT05263180 Phase I EMB-09 A Study of EMB-09 in Participants With Advanced or Metastatic Solid Tumors. Recruiting AUS 1
NCT05269381 Phase I Cyclophosphamide + Neoantigen peptide vaccine + Pembrolizumab + Sargramostim Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors (PNeoVCA) Recruiting USA 0
NCT05272709 Phase Ib/II TT-702 TT-702 in Patients With Advanced Solid Tumours. (CURATE) Recruiting GBR 0
NCT05274451 Phase I LYL797 A Study to Investigate LYL797 in Adults With Solid Tumors Recruiting USA 0
NCT05279300 Phase I CS5001 A Study of CS5001 in Patients With Advanced Solid Tumors and Lymphomas Recruiting USA | AUS 1
NCT05298592 Phase I BMS-986406 + Nivolumab BMS-986406 A Study of BMS-986406 as Monotherapy and Combination Therapies in Participants With Advanced Tumors Recruiting USA | ESP | BEL 3
NCT05306444 Phase I HBM7008 HBM7008 -Study on Subjects With Advanced Solid Tumors Recruiting USA | AUS 0
NCT05317078 Phase I AMG 794 A Phase 1 Safety, Tolerability, and Pharmacokinetics Study of AMG 794 With Claudin 6-positive Non-small Cell Lung Cancer, Epithelial Ovarian Cancer, and Other Malignant Solid Tumor Indications Active, not recruiting USA | AUS 1
NCT05318469 Phase II Ivermectin + Pembrolizumab Ivermectin and Pembrolizumab for the Treatment of Metastatic Triple Negative Breast Cancer Recruiting USA 0
NCT05325866 Phase I Bemarituzumab A Study Evaluating Bemarituzumab in Solid Tumors With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression (FORTITUDE-301) Recruiting USA | ITA | GBR | FRA | ESP | CAN | BEL | AUT | AUS 17
NCT05329532 Phase Ib/II Modi-1 Modi-1 + Pembrolizumab Modi-1 in Breast, Head and Neck, Ovarian, or Renal Cancer (ModiFY) Recruiting GBR 0
NCT05332561 Phase II Olaparib Ipatasertib Sacituzumab govitecan-hziy Inavolisib Pertuzumab/trastuzumab/hyaluronidase-zzxf Atezolizumab Genomics Guided Targeted Post-neoadjuvant Therapy in Patients With Early Breast Cancer (COGNITION-GUIDE) Recruiting DEU 0
NCT05340413 Phase II Olaparib Predicting Olaparib Sensitivity in Patients With Unresectable Locally Advanced/Metastatic HER2-negative Breast Cancer. (RADIOLA) Recruiting ESP 0
NCT05358379 Phase Ib/II CYC140 A Study to Investigate CYC140, in Subjects With Advanced Solid Tumors and Lymphoma Recruiting USA | ESP 1
NCT05358639 Phase I Navitoclax + Olaparib Combination of Olaparib and Navitoclax in Women With HGSC and TNBC Recruiting CAN 0
NCT05368506 Phase I ZN-c3 ZN-c3 for the Treatment of Metastatic Triple-Negative Breast Cancer and Advanced Ovarian Cancer Withdrawn 0
NCT05374512 Phase III Eribulin Nab-paclitaxel Paclitaxel Datopotamab deruxtecan Carboplatin Capecitabine A Study of Dato-DXd Versus Investigator's Choice Chemotherapy in Patients With Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer, Who Are Not Candidates for PD-1/PD-L1 Inhibitor Therapy Recruiting USA | ITA | GBR | FRA | ESP | DEU | CAN | BEL 15
NCT05382286 Phase III Pembrolizumab + Sacituzumab govitecan-hziy Carboplatin + Gemcitabine + Pembrolizumab Paclitaxel + Pembrolizumab Nab-paclitaxel + Pembrolizumab Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice and Pembrolizumab in Patients With Previously Untreated, Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer (ASCENT-04) Recruiting USA | ITA | GBR | FRA | ESP | DEU | CAN | BEL | AUT | AUS 19
NCT05382299 Phase III Nab-paclitaxel Carboplatin + Gemcitabine Sacituzumab govitecan-hziy Paclitaxel Study of Sacituzumab Govitecan-hziy Versus Treatment of Physician's Choice in Patients With Previously Untreated Metastatic Triple-Negative Breast Cancer (ASCENT-03) Recruiting USA | ITA | GBR | FRA | ESP | DEU | CAN | BEL | AUT | AUS 22
NCT05383170 Phase Ib/II Cypep-1 + Pembrolizumab A Study to Evaluate the Safety and Efficacy of CyPep-1 in Combination With Pembrolizumab for the Treatment of Advanced or Metastatic Cancers (Catalyst) Active, not recruiting USA | ITA | FRA | ESP 1
NCT05383196 Phase Ib/II Onvansertib + Paclitaxel Phase 1b/2 Study of Onvansertib + Paclitaxel in Triple-Negative Breast Cancer (TNBC) Recruiting USA 0
NCT05388435 Phase Ib/II SKL27969 Safety, Tolerability, PK/PD & Preliminary Efficacy of SKL27969 in Advanced Solid Tumors Patients Active, not recruiting USA 0
NCT05403554 Phase I NI-1801 A Study of NI-1801 in Patients With Mesothelin Expressing Solid Cancers Recruiting ITA | FRA 0
NCT05422794 Phase I Nab-paclitaxel + Pembrolizumab + ZEN-3694 Testing the Addition of Anti-Cancer Drug, ZEN003694 (ZEN-3694) and PD-1 Inhibitor (Pembrolizumab), to Standard Chemotherapy (Nab-Paclitaxel) Treatment in Patients With Advanced Triple-Negative Breast Cancer Recruiting USA 0
NCT05438329 Phase Ib/II DB-1305 First-in-human Study of DB-1305 for Advanced/Metastatic Solid Tumors Recruiting USA 2
NCT05451784 Phase Ib/II NUMARZU-001 Treatment of Advanced or Metastatic Triple-negative Breast Cancer With Adoptive Therapy of PD1+ TILS (TILS001) Recruiting ESP 0
NCT05451849 Phase Ib/II Cyclophosphamide + Fludarabine TC-510 A Phase 1/2 Trial of TC-510 In Patients With Advanced Mesothelin-Expressing Cancer Active, not recruiting USA 0
NCT05453825 Phase II Irinotecan + Navicixizumab Navicixizumab Navicixizumab + Paclitaxel A Study of Navicixizumab Monotherapy or in Combination in Patients With Select Advanced Solid Tumors Recruiting USA 0
NCT05483491 Phase I Aldesleukin + KK-LC-1 TCR-T cells KK-LC-1 TCR-T Cell Therapy for Gastric, Breast, Cervical, and Lung Cancer Recruiting USA 0
NCT05491226 Phase II Pembrolizumab + SNDX-6352 Reinvigorating TNBC Response to Immunotherapy With Combination Myeloid Inhibition and Radiation Recruiting USA 0
NCT05492682 Phase I Cyclophosphamide + Pembrolizumab + PeptiCRAd-1 START: Safety and Anti-Tumor Activity of PeptiCRAd-1 in Treatment of Cancer Recruiting DEU 0
NCT05498597 Phase I AMT-151 AMT-151 in Patients With Selected Advanced Solid Tumours Recruiting AUS 1
NCT05520723 Phase II Loperamide + Sacituzumab govitecan-hziy + Sargramostim Preventive stRategy for IMMU132-relatED AEs in TNBC (PRIMED) Active, not recruiting ESP 0
NCT05533697 Phase Ib/II mRNA-4359 + Pembrolizumab mRNA-4359 Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Advanced Solid Tumors Recruiting USA | GBR | ESP | AUS 0
NCT05537740 Phase I BAY 3375968 + Pembrolizumab BAY 3375968 A First-in-human Study to Learn How Safe the Study Drug BAY3375968, an Anti-CCR8 Antibody, is, When Given Alone or in Combination With Pembrolizumab, How it Affects the Body, How it Moves Into, Through, and Out of the Body, and to Find the Best Dose in Participants With Advanced Solid Tumors Recruiting USA | GBR | CAN | BEL 1
NCT05539365 Phase Ib/II Pembrolizumab Dendritic Cell-Based Treatment Plus Immunotherapy for the Treatment of Metastatic or Unresectable Triple Negative Breast Cancer Not yet recruiting USA 0
NCT05552001 Phase III Sacituzumab govitecan-hziy Safety and Efficacy Analysis of an Antibody Associated With a Chemotherapy for Patients With a Triple Negative Metastatic Breast Cancer (ISIdE) Recruiting FRA 0
NCT05565417 Phase Ib/II IMT-009 Study of the Monoclonal Antibody IMT-009 in Patients With Advanced Solid Tumors or Lymphomas Recruiting USA 0
NCT05570253 Phase II Eribulin + SDX-7320 Eribulin A Study of SDX-7320 in Combination With Eribulin for People With Breast Cancer Recruiting USA 0
NCT05579366 Phase Ib/II PRO1184 PRO1184 for Advanced Solid Tumors (PRO1184-001) Recruiting USA 1
NCT05582538 Phase II Ceralasertib + Durvalumab + Nab-paclitaxel Ceralasertib Followed by Durvalumab and Nab-paclitaxel Combination in mTNBC Patients (ATRiBRAVE) Recruiting ITA 0
NCT05585034 Phase I Pembrolizumab + XmAb808 Phase 1, First-in-human, Dose-finding and Expansion Study to Evaluate XmAb808 in Combination With Pembrolizumab in Advanced Solid Tumors Recruiting USA 0
NCT05592626 Phase Ib/II STAR0602 A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors (START-001) Recruiting USA | CAN 0
NCT05605509 Phase II Fluorouracil + Irinotecan + Leucovorin + RP-6306 RP-6306 + Trastuzumab Gemcitabine + RP-6306 RP-6306 in Patients With Advanced Cancer Recruiting CAN 0
NCT05607498 Phase I EMB-07 First in Human Study of EMB-07 in Locally Advanced/Metastatic Solid Tumors Recruiting AUS 1
NCT05620134 Phase Ib/II JK08 A Study of JK08, an IL-15 Antibody Fusion Protein Targeting CTLA-4, in Patients With Unresectable Locally Advanced or Metastatic Cancer Recruiting ESP | BEL 0
NCT05620914 Phase I Patritumab deruxtecan A Window of Opportunity Study of Patritumab Deruxtecan in Patients With Brain Metastases (PARAMETer) Not yet recruiting USA 0
NCT05623488 Phase I HuCART-meso cells CAR T Cells in Mesothelin-Expressing Breast Cancer Recruiting USA 0
NCT05625412 Phase I CC-90001 + Nivolumab Capecitabine + CC-90001 CC-90001 CC-90001 + Docetaxel A Study of BMS-986360/CC-90001 Alone and in Combination With Chemotherapy or Nivolumab in Advanced Solid Tumors Recruiting USA | ITA | FRA | ESP | CAN | AUS 3
NCT05629585 Phase III Datopotamab deruxtecan Capecitabine + Pembrolizumab Datopotamab deruxtecan + Durvalumab A Study of Dato-DXd With or Without Durvalumab Versus Investigator's Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Without Pathological Complete Response Following Neoadjuvant Therapy Recruiting USA | ITA | GBR | FRA | ESP | DEU | CAN | BEL 10
NCT05633654 Phase III Pembrolizumab + Sacituzumab govitecan-hziy Capecitabine + Pembrolizumab Pembrolizumab Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05) Recruiting USA 0
NCT05642949 Phase Ib/II MHB036C Study of MHB036C in Participants With Advanced or Metastatic Solid Tumors Not yet recruiting AUS 0
NCT05645380 Phase II Cyclophosphamide + Doxorubicin + Pembrolizumab Carboplatin + Docetaxel + Pembrolizumab Neoadjuvant TIL- and Response-Adapted Chemoimmunotherapy for TNBC (NeoTRACT) Recruiting USA 0
NCT05660083 Phase II Alpelisib + L-NMMA + Nab-paclitaxel Alpelisib/iNOS Inhibitor/Nab-paclitaxel in Patients With HER2 Negative Metaplastic Breast Cancer (MpBC) Recruiting USA 0
NCT05673200 Phase I Decitabine and Cedazuridine + Paclitaxel + Pembrolizumab Testing the Addition of an Anti-cancer Drug, ASTX727 (Cedazuridine, Decitabine), to Chemotherapy (Paclitaxel) and Immunotherapy (Pembrolizumab) for Metastatic Triple-Negative Breast Cancer Recruiting USA 0
NCT05684965 Phase I XTX301 XTX301 in Patients With Advanced Solid Tumors Recruiting USA 0
NCT05700721 Phase II Dostarlimab-gxly + Niraparib Phase II Trial of the PARP Inhibitor Niraparib and PD-1 Inhibitor Dostarlimab in Patients With Advanced Cancers With Active Progressing Brain Metastases (STARLET) Recruiting USA 0
NCT05704985 Phase I DK210 DK210 + Nivolumab Paclitaxel DK210 + Pembrolizumab Oxaliplatin Capecitabine Fluorouracil Carboplatin Evaluating Safety and Biomarkers Using DK210 (EGFR) for Locally Advanced or Metastatic EGFR+ Tumors Recruiting USA 0
NCT05714553 Phase Ib/II Docetaxel + Leucovorin + NUC-3373 Leucovorin + NUC-3373 + Pembrolizumab NUC-3373 in Combination With Other Agents in Patients With Advanced Solid Tumours Recruiting GBR 0
NCT05719558 Phase I ASP1002 A Study of ASP1002 in Adults for Treatment of Solid Tumors Recruiting USA 0
NCT05741164 Phase II Pembrolizumab + Propranolol Propranolol and Pembrolizumab for Tumor Re-sensitization and Treatment of Patients With Checkpoint Inhibitor Refractory Metastatic or Unresectable Triple Negative Breast Cancer Not yet recruiting USA 0
NCT05746897 Phase I NM1F + Pembrolizumab NM1F A First-in-human, Phase I, Open-label, Multicenter Study of NM1F(Anti-PVRIG) in Patients With Advanced Solid Tumors Recruiting USA 0
NCT05756166 Phase Ib/II Celecoxib + Interferon alpha-2b + Pembrolizumab + Rintatolimod Rintatolimod, Celecoxib and Interferon Alpha 2b With Pembrolizumab For the Treatment of Patients With Metastatic or Unresectable Triple Negative Breast Cancer Recruiting USA 0
NCT05812807 Phase III Pembrolizumab Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Pembrolizumab Recruiting USA 1
NCT05826600 Phase I OMX-0407 A Study of OMX-0407 in Patients With Previously Treated Solid Tumours That Can't be Removed Surgically Recruiting ESP 0
NCT05836324 Phase I INCA33890 A Study to Evaluate the Safety of INCA33890 in Participants With Advanced or Metastatic Solid Tumors Recruiting USA | ITA | GBR | FRA | ESP 2
NCT05846789 Phase II Carboplatin + Tocilizumab Carboplatin Phase II Trial of Carboplatin +/- Tocilizumab for Metastatic Triple Negative and ER-low Breast Cancers Recruiting USA 0
NCT05848739 Phase I ST316 A Phase 1-2 of ST316 With Selected Advanced Unresectable and Metastatic Solid Tumors Recruiting USA 0
NCT05852691 Phase II Nab-paclitaxel + RO7247669 Nab-paclitaxel + Pembrolizumab A Study of Tobemstomig + Nab-Paclitaxel Compared With Pembrolizumab + Nab-Paclitaxel in Participants With Previously Untreated, PD-L1-Positive, Locally-Advanced Unresectable or Metastatic Triple-Negative Breast Cancer Recruiting USA | DEU | AUS 7
NCT05865990 Phase II Patritumab deruxtecan HER3-DXd in Breast Cancer and NSCLC Brain Metastases and Solid Tumor Leptomeningeal Disease (TUXEDO-3) Recruiting ESP | AUT 0
NCT05866432 Phase II Datopotamab deruxtecan Phase II Study of Dato-DXd in Triple-negative Breast Cancer Patients With Newly Diagnosed or Progressing Brain Metastases (TUXEDO-2) Recruiting AUT 0
NCT05867251 Phase Ib/II ARTS-021 + Fulvestrant + Palbociclib ARTS-021 + Letrozole + Palbociclib ARTS-021 + Carboplatin ARTS-021 Study of ARTS-021 in Patients With Advanced Solid Tumors Recruiting USA 0
NCT05886868 Phase I BL0020 Phase I Study of BL0020, a Novel Anti-tumor Drug, in Adult Subjects With Advanced Solid Tumors Recruiting AUS 1
NCT05888831 Phase Ib/II BMS-986449 + Nivolumab BMS-986449 A Study of BMS-986449 With and Without Nivolumab in Participants With Advanced Solid Tumors Recruiting USA | ITA | FRA | ESP | BEL 1
NCT05891171 Phase I AB598 + Carboplatin + Pemetrexed Disodium + Zimberelimab AB598 AB598 + Fluorouracil + Leucovorin + Oxaliplatin + Zimberelimab Study of AB598 Monotherapy and Combination Therapy in Participants With Advanced Cancers (ARC-25) Recruiting USA 0
NCT05902988 Phase Ib/II VLS-1488 A Phase I/II Study of VLS-1488 in Subjects With Advanced Cancer Recruiting USA 0
NCT05904496 Phase I BGB-30813 BGB-30813 + Tislelizumab A Study Investigating the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of BGB-30813 Recruiting USA | ESP | AUS 0
NCT05929768 Phase III Cyclophosphamide + Doxorubicin + Pembrolizumab Carboplatin + Docetaxel + Pembrolizumab Carboplatin + Paclitaxel + Pembrolizumab Shorter Chemo-Immunotherapy Without Anthracycline Drugs for Early-Stage Triple Negative Breast Cancer Recruiting USA 1
NCT05947474 Phase I ORB-011 ORB-011 In Patients With Advanced Solid Tumors (ORB) Recruiting USA 0
NCT05958199 Phase I NPX267 Treatment With NPX267 for Subjects With Solid Tumors Known to Express HHLA-2 Recruiting USA 0
NCT05969041 Phase I MT-302 Study of MT-302 in Adults With Advanced or Metastatic Epithelial Tumors (MYE Symphony) Recruiting AUS 0
NCT06008275 Phase I Neratinib + Ruxolitinib Neratinib in Combination With Ruxolitinib in Patients With mTNBC Not yet recruiting USA 0
NCT06014502 Phase I IMGS-001 Study to Evaluate IMGS-001 Treatment in Patients With Relapsed or Refractory Advanced Solid Tumors Recruiting USA 0
NCT06014658 Phase I MBRC-101 Safety & PK of MBRC-101 in Advanced Refractory Solid Tumors Recruiting USA 0
NCT06026657 Phase Ib/II Gemcitabine + TGF-beta-imprinted NK cells Gemcitabine + Naxitamab + TGF-beta-imprinted NK cells Gemcitabine and Ex Vivo Expanded Allogenic Universal Donor, TGFbeta-i Natural Killer (NK) Cells With or Without Naxitamab (Danyelza) for the Treatment of Patients With Metastatic, GD2 Expressing, HER2 Negative Breast Cancer Recruiting USA 0
NCT06027268 Phase II Carboplatin + Gemcitabine + Pembrolizumab + Trilaciclib Phase II Trial of Trilaciclib, Pembrolizumab, Gemcitabine and Carboplatin in Metastatic Triple-Negative Breast Cancer (ToPCourT) Recruiting USA 0
NCT06052852 Phase Ib/II BDC-3042 + Pembrolizumab BDC-3042 Study of BDC-3042 as Single Agent and in Combination With Pembrolizumab in Patients With Advanced Malignancies Recruiting USA 0
NCT06066424 Phase I Cyclophosphamide + Fludarabine TROP2-CAR/IL15-transduced CBNK cells Rimiducid Phase 1 Dose Escalation and Expansion Study of TROP2 CAR Engineered IL15-transduced Cord Blood-derived NK Cells in Patients With Advanced Solid Tumors (TROPIKANA) Recruiting USA 0
NCT06084481 Phase I ABBV-400 Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 Recruiting USA 2
NCT06084689 Phase II BI 907828 + Ezabenlimab Targeting MDMD and PD1 in Tumors With Tertiary Lymphoid Structures (EMPIRE) Not yet recruiting FRA 0
NCT06099769 Phase II Capecitabine Paclitaxel Enzalutamide Enzalutamide + Mifepristone Eribulin Carboplatin A Study of Enzalutamide, Enzalutamide in Combination With Mifepristone, or Chemotherapy in People With Metastatic Breast Cancer Recruiting USA 0
NCT06103864 Phase III Carboplatin + Paclitaxel + Pembrolizumab Carboplatin + Nab-paclitaxel + Pembrolizumab Datopotamab deruxtecan + Durvalumab Datopotamab deruxtecan Carboplatin + Gemcitabine + Pembrolizumab A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer Recruiting USA | GBR | ESP | DEU | CAN | AUS 10
NCT06112379 Phase III Carboplatin + Paclitaxel Cyclophosphamide + Epirubicin + Paclitaxel Capecitabine Carboplatin + Cyclophosphamide + Doxorubicin + Paclitaxel Cyclophosphamide + Doxorubicin + Pembrolizumab Cyclophosphamide + Epirubicin + Pembrolizumab Datopotamab deruxtecan + Durvalumab Cyclophosphamide + Doxorubicin + Paclitaxel Carboplatin + Paclitaxel + Pembrolizumab A Phase III Randomised Study to Evaluate Dato-DXd and Durvalumab for Neoadjuvant/Adjuvant Treatment of Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer Recruiting USA | ITA | GBR | FRA | ESP | DEU | CAN | BEL | AUT | AUS 16
NCT06136884 Phase I AO-252 A First-In-Human, Phase 1 Study Evaluating Oral TACC3 PPI Inhibitor, AO-252, in Advanced Solid Tumors Recruiting USA 0
NCT06154291 Phase Ib/II XON7 FIH XON7 in Advanced/Metastatic Solid Tumors (FIPO23) Recruiting FRA | BEL 0
NCT06162351 Phase II PLX038 A Study to Evaluate the Efficacy and Toxicities of PLX038, in Patients With Locally Advanced or Metastatic Triple-negative Breast Cancer (TOPOLOGY) Not yet recruiting FRA 0
NCT06167317 Phase I GS-0201 + Sacituzumab govitecan-hziy GS-0201 Study of GS-0201 Alone and in Combination in Participants With Advanced Solid Tumors Recruiting USA 0
NCT06171789 Phase Ib/II PRO1107 PRO1107 in Patients With Advanced Solid Tumors Recruiting USA 0
NCT06175390 Phase II Atezolizumab + Nab-paclitaxel + Tiragolumab Atezolizumab + Tiragolumab Atezolizumab + Carboplatin + Nab-paclitaxel + Tiragolumab Atezolizumab + Cyclophosphamide + Doxorubicin + Tiragolumab Tiragolumab, Atezolizumab and Chemotherapy in Triple Negative Breast Cancer (SKYLINE) Recruiting FRA 0
NCT06193525 Phase II Talazoparib FUnctional Selection of Advanced Breast Cancer Patients for Talazoparib Treatment Using the REpair Capacity (RECAP) Test (FUTURE) Recruiting 1
NCT06224673 Phase II ARX-788 ARX788 for Treating Patients With HER2-low Locally Advanced Unresectable or Metastatic Breast Cancer Not yet recruiting USA 0
NCT06238479 Phase I LY4101174 A Study of LY4101174 in Participants With Recurrent, Advanced or Metastatic Solid Tumors Recruiting USA 0
NCT06238921 Phase Ib/II Sacituzumab govitecan-hziy + Zimberelimab Zimberelimab Sacituzumab Govitecan and Zimberelimab w/SRS in the Management of Metastatic Triple Negative Breast Cancer With Brain Metastases Not yet recruiting USA 0
NCT06245889 Phase II Cyclophosphamide Olaparib Carboplatin + Paclitaxel + Pembrolizumab Doxorubicin Capecitabine PET Dynamics to Response-Adapted Neoadjuvant Therapy in TNBC (NeoADAPT) Not yet recruiting USA 0
NCT06246968 Phase I Pembrolizumab A Study of Pembrolizumab and Cryoablation in People With Breast Cancer Recruiting USA 0
NCT06249048 Phase Ib/II Pembrolizumab + STX-001 STX-001 Phase 1/2 Study of IT STX-001 in Patients With Advanced Solid Tumors as Monotherapy or in Combination With Pembrolizumab Not yet recruiting USA | AUS 0
NCT06264921 Phase I NKT3447 A Phase 1 Study With NKT3447 for Adults With Advanced/Metastatic Solid Tumors Not yet recruiting USA 0